Zbirka strokovno pregledanih poročil o primerih in študij, ki navajajo neželene učinke po cepljenju proti COVID.

Znanstvene publikacije in poročila o primerih

Zbirka strokovno pregledanih poročil o primerih in študij, ki navajajo neželene učinke po cepljenju proti COVID.

Raziskovanje neželenih učinkov cepiva proti covidu je lahko delno zastrašujoče zaradi številnih dejavnikov. Predvsem je informacije neverjetno težko najti. Tukaj delimo vedno večji seznam strokovno pregledanih študij, specifičnih za neželene dogodke cepiva proti covidu. Ta seznam pripravlja in vzdržuje naše predano osebje poškodovanih doktorjev znanosti in zdravstvenih delavcev.

Preden se poglobite, si oglejte našo raziskovalno osnovo: Kako brati in razumeti raziskave za orodja, kako najbolje pristopiti k ogromni količini informacij, ki jih najdete v spodnjem dokumentu. Kot vedno, je to samo v informativne namene. Pogovorite se s svojo zdravniško ekipo, ki ji zaupate.

Nam nekaj manjka? Prosimo , pišite nam in nas obvestite.
Različica za tiskanje 2.1

Posodobljeno: 27. 10. 2022 – Dodani primeri Neuro in Kids; 25. 7. 2022 – dodani POTS, tinitus in drugo; 3. 7. 2022 – dodanih 250 nevronov, srca in MIS-V

1250+ strokovno pregledanih publikacij:

Nevrološki | Pljučna | Srčno-žilni | Prebavila | Ledvična | Onkologija | Oftalmologija | Ušesa, nos in grlo | Avtoimunski | MIS-V | AKUŠER | Razno

Nevrološki:

Splošno

Spekter nevroloških zapletov po cepljenju proti COVID-19: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8557950/

Cepljenje z mRNA proti COVID-19, ki vodi do vnetja osrednjega živčevja: serija primerov https://link.springer.com/article/10.1007/s00415-021-10780-7?fbclid=IwAR1WIozzELtGyD_DttkLNZFMcl3yW6iBW9C0v8uRyiYtTulzRvKVPE_xYko

Sistematični pregled primerov demielinizacije CNS po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34839149/

Spekter ugotovitev nevroslikanja pri cepljenju po covidu-19: serija primerov in pregled literature: https://pubmed.ncbi.nlm.nih.gov/34842783/

Nevrološke avtoimunske bolezni po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34668274/

Novonastali avtoimunski pojavi po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34957554/

Nevrološki stranski učinki cepljenja proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34750810/

Potencialni nevrološki učinek cepiv proti COVID-19: pregled https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250748/

Zavrnitev funkcionalnih nevroloških motenj in cepljenja: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26160?fbclid=IwAR3C-QQc-ZDEDoCu0fWNQuVYzvbC3qYHGekCaicU5-l_bOUz4N52jl1wjJ0

Nevrološko varnostno spremljanje cepiv proti COVID-19, izkušnje iz preteklosti za informiranje sedanjosti: https://pubmed.ncbi.nlm.nih.gov/34475124/

Nevrološki neželeni učinki po prvem odmerku zdravila AstraZeneca in okužba s COVID-19: https://pubmed.ncbi.nlm.nih.gov/34697502/

Cepiva proti covidu nimajo nevroloških stranskih učinkov: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206845/

Kombinirana centralna in periferna demielinizacija z anti-neurofascin155 IgG po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35107062/

Raztrganje intrakranialne anevrizme v 3 dneh po prejemu cepljenja z mRNA: 3 poročila o primerih: https://pubmed.ncbi.nlm.nih.gov/35509565/

Cerebrovaskularni zapleti COVID-19 in cepljenja proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/35420916/

nevropatija

 Nevropatija majhnih vlaken in POTS po cepljenju Moderna in Pfizer (objava NIH): https://www.medrxiv.org/content/10.1101/2022.05.16.22274439v1?fbclid=IwAR3bhFglz5CRfS4zFd1QAP0bvIuk7XDXq7fDQxZwTYj0IzPE9C32lXDGqd

Nevropatija majhnih vlaken: https://onlinelibrary.wiley.com/doi/10.1002/mus.27251

Cepljenja proti COVID-19 morda niso zapletena samo zaradi GBS, ampak tudi zaradi distalne nevropatije majhnih vlaken: https://pubmed.ncbi.nlm.nih.gov/34525410/

Možni mehanizmi nevropatij, povezanih s cepljenjem proti covidu-19: https://pubmed.ncbi.nlm.nih.gov/35119106/

Akutne vnetne nevropatije s cepivi proti COVID-19: analiza nesorazmernosti podskupin v VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/

Polinevropatija pri 43yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35753790/

Ponovni pojav hude polinevropatije po prejemu cepiva Pfizer pri bolniku z anamnezo eozinofilne granulomatoze s poliangiitisom: https://pubmed.ncbi.nlm.nih.gov/35487626/

POTS (sindrom posturalne ortostatske tahikardije):

(Glejte publikacijo NIH v razdelku o nevropatiji zgoraj)

Sindrom posturalne ortostatske tahikardije po cepljenju z mRNA proti COVID-19: https://link.springer.com/article/10.1007/s10286-022-00880-3 https://pubmed.ncbi.nlm.nih.gov/35870086/

POTS po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/33968543/ https://www.cureus.com/articles/56242-a-case-of-postural-orthostatic-tachycardia-syndrome-secondary- to-the-messenger-rna-covid-19-cepivo

Avtonomna disfunkcija po inokulaciji s cepivom ChAdOx1 nCoV-19 https://academic.oup.com/ehjcr/article/5/12/ytab472/6444985

5 primerov POTS po cepljenju, stari 17 let in več: https://pubmed.ncbi.nlm.nih.gov/35870086/

Nevralgija:

Nevralgija – trigeminalna, amitrofija: trigeminalni nevritis po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34870807/

Nevralgija trigeminusa in cervikalni radikulitis po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34155020/

Nevralgična amiotrofija po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34347105/

Amiotrofična nevralgija kot posledica zdravila AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34330677/

Nevralgična amiotrofija lumbosakralnega pleksusa po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34816739/

Parsonage-Turnerjev sindrom po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34559695/

Parsonage-Turnerjev sindrom pri 43-letniku po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34936579/

2 primera Parsonage Turnerjevega sindroma po Moderni in Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34402669/

Parsonage-Turnerjev sindrom po Astra Zeneci: poročilo o primeru in pregled literature: https://pubmed.ncbi.nlm.nih.gov/34903275/

Transverzalni mielitis:

Cepivo proti COVID-19 je povzročilo transverzalni mielitis MOGAD pri 15-letniku: https://pubmed.ncbi.nlm.nih.gov/35626851/

36 let s transverzalnim mielitisom po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/33787891/

27 let z cervikalnim transverzalnim mielitisom po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/35756190/

Akutni mielitis po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34392078/

67 let s transverzalnim mielitisom po 1. odmerku zdravila Moderna: https://pubmed.ncbi.nlm.nih.gov/34482455/

70-letni z akutnim avtoimunskim transverzalnim mielitisom po Moderni: https://pubmed.ncbi.nlm.nih.gov/34941191/

Longitudinalni ekstenzivni transverzalni mielitis po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34507942/

Longitudinalni ekstenzivni transverzalni mielitis pri 25yoF po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34641797/

Longitudinalni ekstenzivni transverzalni mielitis po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34182207/

Akutni transverzalni mielitis po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34684047/

Transverzalni mielitis in Bellsova paraliza po cepljenju J&J: https://pubmed.ncbi.nlm.nih.gov/34458035/

Akutni transverzalni mielitis pri 43 bolnikih po cepljenju z zdravilom AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/33981305/

Longitudinalni ekstenzivni mielitis, povezan z MOG-protitelesi po zdravilu AstraZeneca pri 59-letniku: https://pubmed.ncbi.nlm.nih.gov/34931927/

Bolezen, povezana s protitelesi MOG (38 let) in transverzalni mielitis (39 let) po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35755241/

GBS (Guillain Barrejev sindrom):

12 primerov GBS in 4 primeri CIDP po cepljenju proti COVID-19 v Združenem kraljestvu: https://pubmed.ncbi.nlm.nih.gov/34786740/

24 primerov GBS po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34967005/

Senzorični GBS pri 16yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35097156/

Senzorični ataksični GBS z imunoglobulinom G protiteles proti GM1 po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34871447/

AstraZeneca in GBS: analiza z uporabo nacionalne baze podatkov o imunoglobulinih: https://pubmed.ncbi.nlm.nih.gov/35180300/

GBS po Johnsonu in Johnsonu: https://www.onlinescientificresearch.com/articles/the-development-of-guillain-barre-syndrome-subsequent-to-administration-of-ad26cov2s-vaccine.pdf

GBS po 2. odmerku Pfizerja: elektromionevrografija in laboratorijski izvidi: https://pubmed.ncbi.nlm.nih.gov/34347563/

 3 primeri GBS v Alberti po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/35747886/

GBS v 23-letniku, ki sledi Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35528113/

Senzorični ataksični GBS pri 80-letnem bolniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35342134/

GBS pri 58 let starosti s hitrim nastopom in avtonomno disfunkcijo po 1. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/35401916/

GBS v 80-letnici, ki sledi Moderni: https://pubmed.ncbi.nlm.nih.gov/35441015/

GBS pri 25 letih po 2. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/34346014/

GBS sledi Pfizerju v 42-letniku: https://pubmed.ncbi.nlm.nih.gov/34779385/

GBS v 42yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34567447/

GBS v 61-letniku, ki sledi Moderni: https://pubmed.ncbi.nlm.nih.gov/34484780/

GBS pri 65-letnem bolniku s presaditvijo jeter po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34431208/

GBS pri 67-letniku po 1. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/34796417/

GBS v 73-letniku, ki sledi Moderni: https://pubmed.ncbi.nlm.nih.gov/34477091/

GBS v starosti 73 let po 2. odmerku Pfizerja: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253659/

GBS v starosti 82 let po prvem odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/33758714/

GBS 10 dni po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34272622/

GBS 11 dni po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34187803/

GBS po AstraZeneci z edemom papile kot atipičnim začetkom: https://pubmed.ncbi.nlm.nih.gov/34418708/

GBS po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34330729/

GBS pri 63-letnem bolniku, ki je imel predhodni sindrom GBS, povezan s cepivom, po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34810163/

Recurrent GBS following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34468703/

3 cases of GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34548920/

3 cases of GBS and 1 case of CIDP following AstraZeneca in Tasmania: https://pubmed.ncbi.nlm.nih.gov/34560365/

7 cases of GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34114256/

19 cases of GBS following J&J, Pfizer, and Astra Zeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34644738/

GBS following vaccination, a review of 39 cases: https://pubmed.ncbi.nlm.nih.gov/34648420/

2 cases of Sensory GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416410/

Bilateral facial weakness with paresthesia variant of GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34261746/

Bifacial diplegia variant of GBS following J&J vaccination: https://pubmed.ncbi.nlm.nih.gov/34449715/

GBS presenting as bifacial diplegia in 2 patients following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34649856/

 GBS following Johnson and Johnson: https://pubmed.ncbi.nlm.nih.gov/34550109/

GBS following Moderna: https://pubmed.ncbi.nlm.nih.gov/34767184/

GBS following 1st dose AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34217513/ 

GBS with Prominent Facial Diplegia after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34808658/

GBS in a 14yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34717201/

GBS in a 21yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34981285/

GBS in a 38yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34988954/

GBS in a 49yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34703690/

2 primera GBS po Pfizerju pri bolnikih v remisiji b-celičnega limfoma: https://pubmed.ncbi.nlm.nih.gov/34929194/

2 primera GBS po Pfizerju in AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34593364/

GBS po cepljenju proti COVID-10: poročilo o dveh primerih: https://pubmed.ncbi.nlm.nih.gov/34599482/

Različica obrazne diplegije GBS pri 38-letniku po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34538679/

Različica obrazne diplegije GBS pri 65-letniki po J&J: https://pubmed.ncbi.nlm.nih.gov/34447646/

Aksonska različica GBS pri 86yoF, začasno povezana s cepljenjem Moderna: https://pubmed.ncbi.nlm.nih.gov/34722067/

Miller Fisherjev sindrom:

Miller Fischerjev sindrom in sindrom prekrivanja GBS po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34848426/

Miller Fisherjev sindrom pri 24 letih po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34817727/

Miller Fisherjev sindrom pri 71-letniku, ki je spremljal Pfizer: https://pubmed.ncbi.nlm.nih.gov/34789193/

Miller Fisherjev sindrom po 2. odmerku cepljenja Pfizer pri bolniku z rešenim covidom-19 https://pubmed.ncbi.nlm.nih.gov/34808657/

 

Encefalopatija:

75 let z akutno hemoragično nekrotizirajočo encefalopatijo po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/35098489/

32 let z akutno hiperaktivno encefalopatijo po Moderni z dramatičnim odzivom na metilprednizolon: https://pubmed.ncbi.nlm.nih.gov/34512961/

Oslabelost obraza, šibkost okončin, encefalopatija in huda neodzivna ITP po Moderni: https://pubmed.ncbi.nlm.nih.gov/33854395/

77 let z akutno encefalopatijo in NSTEMI po Moderni: https://pubmed.ncbi.nlm.nih.gov/34703815/

 

CIDP:

Kronična vnetna demielinizirajoča polinevropatija po spremljanju Moderne: https://pubmed.ncbi.nlm.nih.gov/35651399/

CIPD pri ženski srednjih let, ki spremlja Moderno: https://pubmed.ncbi.nlm.nih.gov/35071987/

Akutna kronična vnetna demielinizirajoča polinevropatija (CIDP) po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34607818/

Kronična vnetna demielinizirajoča polinevropatija po cepljenju z AstraZeneco: https://pubmed.ncbi.nlm.nih.gov/34960248/

 

akatizija:

Prehodna akatizija po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34113842/

 

fantosmija:

Phantosmia: https://pubmed.ncbi.nlm.nih.gov/34096896/

 

Bells paraliza/paraliza živcev:

Več paraliz kranialnih živcev po cepljenju proti COVID-19 (Pfizer): https://pubmed.ncbi.nlm.nih.gov/34725821/

Akutna paraliza abducensnega živca po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34044114/

Akutna paraliza aducensnega živca po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34851785/

Akutna paraliza abducensovega živca po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34827043/

21-letna medicinska sestra s paralizo Bells spremlja Pfizer: https://pubmed.ncbi.nlm.nih.gov/34322761/

34 let z Bells Palsy 2 dni po Moderni: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143982/

36 let z Bellsovo paralizo, mravljinčenje/otrplost/šibkost leve roke po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34336436/

32 let z Bells Palsy spremlja Pfizer: https://pubmed.ncbi.nlm.nih.gov/35759681/

37 let s paralizo Bells po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/33611630/

50-letnik s paralizo Bells po Pfizerju, stalni simptomi po 21 dneh: https://pubmed.ncbi.nlm.nih.gov/34330676/

57 let s paralizo Bells <36 ur po 2. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/33594349/

61yoM with Bells Palsy after each dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34281950/

Bells Palsy following mRNA and inactivated (CoronaVac) vaccines: a case series and nested case-control study: https://pubmed.ncbi.nlm.nih.gov/34411532/

Rate of Bells Palsy following mRNA vaccination is 2-3x higher then expected: https://pubmed.ncbi.nlm.nih.gov/34111409/

Neuromyelitis Optica:

Novonastala motnja optičnega spektra nevromielitisa po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35184119/

Optični nevromielitis pri zdravi ženski po Moderni: https://pubmed.ncbi.nlm.nih.gov/34660149/

Motnja optičnega spektra nevromielitisa (NMOSD): https://link.springer.com/article/10.1007/s10072-021-05427-4?fbclid=IwAR2DGcW8Y5UxvdzcOQaBUPn6_RTZGQRSsNo6bzanyAm9yN6387E3Z6WrKlI

Motnja optičnega spektra nevromielitisa s pozitivnim protitelesom po 2. odmerku Pfizerja pri 80-letnem bolniku: https://pubmed.ncbi.nlm.nih.gov/35761845/

Optična nevropatija po Pfizerju in Astrazeneci: poročilo dveh primerov: https://pubmed.ncbi.nlm.nih.gov/34906029/

Bilateralni optični nevritis po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/35098359/

Optični nevritis in transverzalni mielitis pri bolnikih z MS po cepljenju z Astrazeneco: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205198/

multipla skleroza:

Pacientov prvi MS Flare po Pfizerju https://link.springer.com/article/10.1007/s00415-021-10648-w

Nov pojav MS pri bolniku, starem 32 let, ki je prejemal zdravilo Pfizer: https://pubmed.ncbi.nlm.nih.gov/34804388/

Nov pojav MS pri 40yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34700047/

3 novi primeri MS, 13 izbruhov MS po cepljenju Pfizer, Moderna in Astra Zeneca: https://pubmed.ncbi.nlm.nih.gov/34744992/

4 primeri aktivacije stabilne MS, 2 primera nove MS, 1 primer novonastalega nevromielitisa optica po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34480607/

Okužba s COVID in rezultati cepljenja pri multipli sklerozi: https://pubmed.ncbi.nlm.nih.gov/35747550/

Huda ponovitev multiple skleroze po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34447349/

5 primerov nove diagnoze multiple skleroze po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34922126/

Optični nevritis in transverzalni mielitis pri bolnikih z MS po cepljenju z Astrazeneco: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205198/

Myasthenia Gravis:

Vaccination associated Ocular Myasthenia Gravis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35077038/

Myasthenia Gravis Flare Following Moderna: https://www.cureus.com/articles/60348-a-case-of-covid-19-vaccine-causing-a-myasthenia-gravis-crisis

Fatal Myasthenic Crisis in a 55yoM following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35449619/

New onset Myasthenia Gravis in 82yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709075/

Cerebral Venous Thrombosis:

Thromboembolic events following mRNA COVID vaccination, a case series: https://pubmed.ncbi.nlm.nih.gov/35118582/

CVA and Thrombocytopenia following Astrazeneca: https://pubmed.ncbi.nlm.nih.gov/34175640/

Cerebral venous sinus thrombosis after Moderna in a 56yoF: https://pubmed.ncbi.nlm.nih.gov/35181646/

Obsežna tromboza cerebralnih venskih sinusov po 1. odmerku Pfizerja brez TTS pri 28 let starosti: https://pubmed.ncbi.nlm.nih.gov/35136010/

Cerebralna venska tromboza zaradi VITT po 2. odmerku zdravila AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35263427/

Starostno stratificirano tveganje za trombozo cerebralnih venskih sinusov po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34921101/

Značilnosti izidov pri bolnikih s trombozo cerebralnih venskih sinusov pri imunski trombotični trombocitopeniji, povzročeni s cepivom COVID: https://pubmed.ncbi.nlm.nih.gov/34581763/

Tromboza cerebralnih venskih sinusov v okviru cepljenja proti COVID-19: sistematični pregled in metaanaliza: https://pubmed.ncbi.nlm.nih.gov/35394172/

Ameriška poročila o primerih tromboze cerebralnega venskega sinusa s trombocitopenijo po J&J: https://pubmed.ncbi.nlm.nih.gov/33929487/

Cerebralna venska tromboza pri 61-letniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34796065/

Tromboza cerebralnega venskega sinusa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34783932/

Tromboza centralnega venskega sinusa s subarahnoidno krvavitvijo pri 45-letniku po Moderni: https://pubmed.ncbi.nlm.nih.gov/34478433/

Tromboza cerebralnega venskega sinusa po AstraZeneci, nevrološko in radiološko zdravljenje: https://pubmed.ncbi.nlm.nih.gov/34327553/

Tromboza cerebralnih venskih sinusov, subarahnoidna krvavitev in trombocitopenija po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34485807/

Cerebralna venska sinusna tromboza, pregled evropskih primerov: https://pubmed.ncbi.nlm.nih.gov/34293217/

Pregled evropskih podatkov o cerebralni venski trombozi s citopenijo, opaženih pri Pfizer, Moderna in AstraZeneca https://pubmed.ncbi.nlm.nih.gov/34375510/

Multicentrična kohortna študija cerebralne venske tromboze po cepljenju z zdravilom AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34370972/

Endovaskularno zdravljenje tromboze cerebralnih venskih sinusov in trombocitopenije, ki jo povzroča AstraZeneca, poročilo o 3 primerih: https://pubmed.ncbi.nlm.nih.gov/34782400/

45 primerov cerebralne venske tromboze: https://pubmed.ncbi.nlm.nih.gov/34288044/

Poročilo Mednarodnega konzorcija za cerebralno vensko trombozo o cerebralni venski trombozi po cepljenju proti SARS-COV-2: https://pubmed.ncbi.nlm.nih.gov/34462996/

Spontana redka visceralna psevdoanevrizma z rupturo po Moderni: https://pubmed.ncbi.nlm.nih.gov/34480824/

 

Intracerebralna krvavitev / možganska kap / itd.:

Usodni ICH po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34477089/

ICH zaradi vaskulitisa po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34783899/

Zdravljenje akutne ishemične možganske kapi, povezane z imunsko trombotično trombocitopenijo, ki jo povzroči AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34461442/

Simptomatska pendukularna, kavernozna krvavitev po ITP, povzročeni s cepljenjem Pfizer: https://pubmed.ncbi.nlm.nih.gov/34549178/

Lobarna krvavitev z rupturo prekata kmalu po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34729467/

Dvostranska talamična kap po Pfizerju: primer VITT? https://pubmed.ncbi.nlm.nih.gov/34820232/

 

Aphasia:

Aphasia 7 days after 2nd dose of mRNA based vaccine due to intracerebral bleeding in left temporal lobe: https://pubmed.ncbi.nlm.nih.gov/34192245/

Neuro-Oncologic:

Worsening Neuro-Oncologic Disease Symptoms following mRNA vaccination: https://www.cureus.com/articles/61880-new-onset-neurologic-symptoms-and-related-neuro-oncologic-lesions-discovered-after-covid-19-vaccination-two-neurosurgical-cases-and-review-of-post-vaccine-inflammatory-responses

 

Headache / Aseptic Meningitis:

Zoster Meningitis in a 12yoM following 1st dose Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/35680126/

18yoM with aseptic meningitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34711784/

Aseptični meningitis, mukokutane lezije in artritis po Pfizerju pri 15-letniku: https://pubmed.ncbi.nlm.nih.gov/35214783/

Aseptični meningitis pri 34yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34882515/

Glavobol po AstraZeneci: kohortni center za opazovanje MultiCenter: https://pubmed.ncbi.nlm.nih.gov/34313952/

Status migrenozus po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34807361/

Značilnosti glavobola, povzročenega s cepivom COVID: https://pubmed.ncbi.nlm.nih.gov/34510919/

Klinične značilnosti glavobola po Pfizerju, multicentrični opazovalni kohortni študiji: https://pubmed.ncbi.nlm.nih.gov/34405142/

Aseptični meningitis po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34378098/

Aseptični meningitis po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34777795/

Aseptični meningitis, ki se odziva na steroide, po Pfizerju pri 62 let starosti: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566612/

 

Encefalitis/delirij:

Delirij pri starejšem bolniku po cepljenju: https://pubmed.ncbi.nlm.nih.gov/33829614/

Dva primera encefalopatije in napadov po Moderni: https://pubmed.ncbi.nlm.nih.gov/34367780/

Akutni meningoencefalitis pri 72 let po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35283382/

Akutni encefalitis po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/35748025/

Encefalitis proti LGI1 po cepljenju proti COVID-19: serija primerov: https://pubmed.ncbi.nlm.nih.gov/35751687/

69 let z akutno prehodno encefalopatijo po Moderni: https://pubmed.ncbi.nlm.nih.gov/35702446/

Akutni diseminirani encefalitis po Pfizerju: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294707/

Akutni diseminirani encefalomielitis (ADEM) po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34735684/

ADEM z dvostranskim optičnim nevritisom po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35151258/

Akutni diseminirani encefalomielitis (ADEM) pri 88YF po cepljenju Pfizer: https://pubmed.ncbi.nlm.nih.gov/34841097/

Avtoimunski encefalitis, ki ga povzroča COVID-19 Moderna, pri 48-letniku: https://pubmed.ncbi.nlm.nih.gov/35182374/

Encefalitis proti LGI1 pri 48-letniku po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/35751687/

Autoimmune encephalitis in a 35yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35021289/

Case report of AstraZeneca associated encephalitis in a 22yoF: https://pubmed.ncbi.nlm.nih.gov/34903200/

Akutni diseminirani encefalitis pri mladi samici po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34480527/

Encefalitis po cepljenju po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34324214/

Akutni encefalitis, mioklonus in sladki sindrom po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34312136/

Akutna psihoza zaradi encefalitisa proti NMDA pri mladi ženski v svojih 20-ih po cepljenju Pfizer: https://pubmed.ncbi.nlm.nih.gov/34803896/

Prva epizoda psihoze pri 18 letih po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/35091388/

Novonastala psihoza pri 31-letniku po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34388513/

 

drugo:

Parkinsonova bolezen, povezana s cepivom COVID-19, signal prionske bolezni v zbirki neželenih dogodkov rumenega kartona v Združenem kraljestvu: https://www.semanticscholar.org/paper/COVID-19-Vaccine-Associated-Parkinson%27s-Disease%2C-A- Classen/0fe033bb1e274f27bc7c1703f09206e2965c75ca

Cepiva proti COVID-19 na osnovi RNA in tveganje za prionsko bolezen: https://www.semanticscholar.org/paper/COVID-19-RNA-Based-Vaccines-and-the-Risk-of-Prion-Classen/68580738ad152158a095c2f90a2a28a4c8b5d7d2

Klinično in radiološko spremljanje hemihoreje hemibalizma, ki jo je povzročil Pfizer, pri 90-letnem: https://pubmed.ncbi.nlm.nih.gov/35646423/

Polyneuritis cranialis, redka različica GBS, povezana s Pfizerjem v starosti 16 let: https://pubmed.ncbi.nlm.nih.gov/35062795/

Reverzibilni radikulomielitis po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/35110289/

Huda diskinezija pri bolniku s Parkinsonovo boleznijo po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34368991/

Hemihoreja po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34811599/

3 primeri poslabšanja kompleksnega regionalnega bolečinskega sindroma po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34809486/

Cytotoxic lesion of the Corpus Callousum following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34402238/

Myeloperoxidase anti-neutrophil cytoplasmic antibody positive optic perineuritis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34432055/

Dva bolnika s shizofrenijo, zdravljena s klozapinom, sta po cepivu proti COVID-19 razvila nevtropenijo: https://pubmed.ncbi.nlm.nih.gov/35115846/

Trije primeri: CVA, paraliza levega obraznega živca in mielitis, vsi po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34507266/

pljučni:

S cepivom povzročena intersticijska pljučna bolezen pri 86yoM po cepivu mRNA: https://pubmed.ncbi.nlm.nih.gov/34362838/

Intersticijska pljučna bolezen, ki jo povzroči cepivo: https://pubmed.ncbi.nlm.nih.gov/34510014/

Zapoznela preobčutljivost za Pfizer, ki se kaže s pnevmonitisom in izpuščajem: https://pubmed.ncbi.nlm.nih.gov/34813953/

Cepivo Pfizer je povzročilo vnetje pljuč pri 65-letniku: https://pubmed.ncbi.nlm.nih.gov/34707048/

Intersticijska pljučna bolezen pri 71 let po prejemu cepiva mRNA: https://pubmed.ncbi.nlm.nih.gov/35223425/

2 primera (67 let in 70 let) intersticijske pljučne bolezni, povezane s Pfizerjem: https://pubmed.ncbi.nlm.nih.gov/35355663/

Pljučna embolija in DVT pri 14-letniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35173114/

2 primera eozinofilne pljučnice po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34803208/

Intersticijska pljučna bolezen po cepljenju proti COVID-19 je lahko pogostejša pri Azijcih: https://pubmed.ncbi.nlm.nih.gov/34850213/

Akutna eozinofilna pljučnica pri 37-letnem M po cepljenju Pfizer: https://pubmed.ncbi.nlm.nih.gov/34803207/

Akutna eozinofilna pljučnica po cepljenju z AstraZeneco: https://pubmed.ncbi.nlm.nih.gov/34812326/

Pljučna embolija po Moderni: https://pubmed.ncbi.nlm.nih.gov/34452028/  

2 primera pljučne embolije po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34804412/

 

Srčni:

Splošno:

Utemeljitev za zdravljenje simptomov, ki so se pojavili po dolgotrajni bolezni COVID-19 in po vaxu – pogled kardiologov: https://www.frontiersin.org/articles/10.3389/fcvm.2022.992686/abstract

Cardiovascular and hematological events post COVID-19 vaccination: a systemic review: https://pubmed.ncbi.nlm.nih.gov/34967105/

American Heart Association: Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583

American Heart Association: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines https://www.ahajournals.org/doi/abs/10.1161/circ.144.suppl_1.10712

Note the distinction between myocarditis, novel coronavirus myocarditis, and covid-19 vaccine associated myocarditis: https://pubmed.ncbi.nlm.nih.gov/34791441/

JAMA article, concerns for perimyocarditis underreporting, review of 40 hospitals: https://jamanetwork.com/journals/jama/fullarticle/2782900

Intravenous injection of mRNA vaccine can induce acute myopericarditis in mouse model: https://pubmed.ncbi.nlm.nih.gov/34406358/

The Novel platform of mRNA vaccines and myocarditis: clues into the potential underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/

Proposed pathogenesis, characteristics, and management of mRNA related myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34817850/

mRNA and Pericarditis/myocarditis risk compared to other vaccine types:  https://pubmed.ncbi.nlm.nih.gov/34834458/

ACS risk factor biomarkers increase after mRNA vaccination: https://www.thecardiologyadvisor.com/home/topics/acs/acute-coronary-syndrome-acs-biomarkers-mrna-covid19-vaccine/?s=09&fbclid=IwAR2SRmzW0Aj1dESMuJlTTcZHAHbRIIdl6C2Hpztm8Co_46AV5qss_4-3NV8

Pregled neželenih učinkov na srce pri Pfizerju in Moderni v Singapurju: https://pubmed.ncbi.nlm.nih.gov/34808708/

Smrtni fulminantni nekrotizirajoči eozinofilni miokarditis po prvem odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/34978002/

Imunsko posredovana nekrotizirajoča miopatija po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34970746/

Huda nekrotizirajoča miopatija po Pfizerju in režimu ipulimumaba in nivolumaba pri bolniku z napredovalim melanomom: https://pubmed.ncbi.nlm.nih.gov/34661938/

Miokarditis – perikarditis – Poročila:

odmerku Pfizerja Miokarditis pri 8-letniku po 2. : https://pubmed.ncbi.nlm.nih.gov/35892184/

Miokarditis pri 13-letnih monohorionskih diamniotskih dvojčkih po 2. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/36008643/

Miokarditis pri 15-letniku po 2. odmerku Pfizerja s poznim povečanjem gadolinija na MRI srca, ki traja v akutni fazi: https://pubmed.ncbi.nlm.nih.gov/36074060/

5 primerov miokarditisa, povzročenega s cepivom covid-19, pri 5 najstnikih, serija primerov z nadaljnjim spremljanjem: https://pubmed.ncbi.nlm.nih.gov/35329143/

Pregled 40 primerov miokarditisa pri mladostnikih v Južni Koreji po cepljenju proti covidu-19: https://pubmed.ncbi.nlm.nih.gov/35626870/

Sistematični pregled 53 primerov miokarditisa v starostnem razponu od 14 do 80 let: https://pubmed.ncbi.nlm.nih.gov/35782472/

1077 primerov miokarditisa in 1149 perikarditisa po cepljenju pri nordijskih prebivalcih, kohortna študija: https://pubmed.ncbi.nlm.nih.gov/35442390/

1626 primerov miokarditisa v VAERS od decembra 2020 do avgusta 2021, pregled (JAMA): https://pubmed.ncbi.nlm.nih.gov/35076665/

Miokarditis/mioperikarditis pri 269 posameznikih, populacijska danska kohortna študija: https://pubmed.ncbi.nlm.nih.gov/34916207/

Miokarditis pri mladostnikih in odraslih po cepljenju v letu 2021, pregled 238 primerov: https://pubmed.ncbi.nlm.nih.gov/35449353/

Pregled 40 objavljenih primerov miokarditisa po cepljenju proti covidu: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887934/

Ponovitev mioperikarditisa pri 27-letniku po 3. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/35602257/

Z biopsijo dokazan fulminantni miokarditis pri 48-letniku po 2. odmerku zdravila Moderna: https://pubmed.ncbi.nlm.nih.gov/35187464/

Fulminantni miokarditis pri 80-letnem bolniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35088026/

8 primerov miokarditisa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34133884/

Cepivo proti COVID-19, miokardni infarkt in Kounisov sindrom: https://pubmed.ncbi.nlm.nih.gov/35104343/

Miokarditis pri 17-letniku po cepljenju: https://pubmed.ncbi.nlm.nih.gov/35105392/

4 primeri miokarditisa po poživitvi Pfizer v Izraelu: https://pubmed.ncbi.nlm.nih.gov/35100809/

Moderna povezan mioperikarditis pri bolniku s subklinično avtoimunsko nagnjenostjo: https://pubmed.ncbi.nlm.nih.gov/34868402/

Perimiokarditis pri najstnikih: https://pubmed.ncbi.nlm.nih.gov/34077949/

Miokarditis, povezan s cepljenjem pri mladostnikih: https://pubmed.ncbi.nlm.nih.gov/34389692/

Cepljenje proti mRNA in miokarditis pri mladostnikih: https://pubmed.ncbi.nlm.nih.gov/34393110/

Povezava miokarditisa s cepljenjem z mRNA, pregled primera pri otrocih: https://pubmed.ncbi.nlm.nih.gov/34374740/

Mimik STEMI: žariščni miokarditis pri mladostniku po cepljenju mRNA proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34756746/

Ponovni pojav miokarditisa po cepljenju https://pubmed.ncbi.nlm.nih.gov/34166671/

Akutna miokardna poškodba po cepljenju proti COVID-19: poročilo o primeru in pregled trenutnih dokazov VAERS: https://pubmed.ncbi.nlm.nih.gov/34219532/

Myocarditis in a 27yoM following Pfizer: CMR features: https://pubmed.ncbi.nlm.nih.gov/35626190/

Myocarditis in a 17yo Japanese male following Moderna: https://pubmed.ncbi.nlm.nih.gov/35495897/

Myocarditis and/or pericarditis after mRNA vaccination: head to head comparison of Moderna versus Pfizer: https://pubmed.ncbi.nlm.nih.gov/35750537/

Fulminant myocarditis requiring ECMO in a 60yoF following 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35650138/

Akutni perikarditis po spodbujevalniku mRNA: https://pubmed.ncbi.nlm.nih.gov/35308666/

Miokarditis ali perikarditis po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/35749119/

Miokarditis s hemoragičnim perikardialnim izlivom po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35646594/

Mioperikarditis pri mladih odraslih, ki se obrnejo na urgentno službo: https://pubmed.ncbi.nlm.nih.gov/34310793/

Perikarditis po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34364831/

Simptomatski perikarditis po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34693198/

Miokarditis po J&J pri zdravem, mladem moškem: https://pubmed.ncbi.nlm.nih.gov/34420869/

Akutni miokarditis po Moderni pri mladem moškem: https://pubmed.ncbi.nlm.nih.gov/34308326/

Miokarditis pri zdravem moškem: https://pubmed.ncbi.nlm.nih.gov/34229940/

Akutni miokarditis po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34331307/

Akutni miokarditis po Pfizerju pri zdravem moškem s predhodno okužbo s COVID: https://pubmed.ncbi.nlm.nih.gov/34367386/

Akutni fulminantni miokarditis po cepljenju z mRNA, ki zahteva ECMO: https://pubmed.ncbi.nlm.nih.gov/34778411/

Prikaz primera miokarditisa: https://pubmed.ncbi.nlm.nih.gov/34118375/

Prikaz primera: verjeten miokarditis po cepljenju z mRNA pri bolniku z aritmogeno kardiomiopatijo levega prekata: https://pubmed.ncbi.nlm.nih.gov/34712717/

Miokarditis po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34393273/

Pozna predstavitev miokarditisa, ki ga povzroči cepivo: https://pubmed.ncbi.nlm.nih.gov/34660088/

Miokarditis pri 24 letih: https://pubmed.ncbi.nlm.nih.gov/34268277/

Miokarditis pri 24-letni medicinski sestri po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34400043/

Miokarditis pri 15-letniku, ki spremlja Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369878/

Mioperikarditis pri 16-letniku po cepljenju https://pubmed.ncbi.nlm.nih.gov/34133825/

Miokarditis pri 16 let, pozno povečanje gadolinija: https://pubmed.ncbi.nlm.nih.gov/34778788/

Myocarditis in a 22yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34348657/

4 cases of myocarditis after 3rd dose of Pfizer: magnetic resonance imaging study (18-44yo): https://pubmed.ncbi.nlm.nih.gov/35310989/

5 cases of myocarditis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34092429/

7 cases of myocarditis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35479661/

Myocarditis presenting with hyperechoic nodule in a 17yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35470603/

Myocarditis in a 18yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34804729/

Myocarditis in a middle aged male with significant left ventricular dysfunction following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34795198/

70yoF with myocarditis following J&J Vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270733/

Biopsy proven lymphocytic myocarditis following 1st mRNA vaccination in a 40yo: https://pubmed.ncbi.nlm.nih.gov/34487236/

Cardiac imaging of acute myocarditis following mRNA in a 24yoM: https://pubmed.ncbi.nlm.nih.gov/34402228/

Cardiac MRI findings in young adults following mRNA vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34496880/

Case report: probable myocarditis after mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/

Myocarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34393273/

A rare case of myocarditis and pulmonary embolism after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35343473/

A late presentation of vaccine induced myocarditis: https://pubmed.ncbi.nlm.nih.gov/34660088/

5 cases of myocarditis after Pfizer (age 16 and up): https://pubmed.ncbi.nlm.nih.gov/34092429/

Myocarditis in a 13yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35475062/

Follow-up cardiac magnetic resonance in 7 children with Pfizer vaccine associated myocarditis (80% with persistent abnormalities at 90 days): https://pubmed.ncbi.nlm.nih.gov/35482094/

7 cases of myocarditis after mRNA vaccination (age 16 and up): https://pubmed.ncbi.nlm.nih.gov/35479661/

Followup CMR imaging in 15 patients 6 months after Pfizer associated myocarditis (age 14-19): https://pubmed.ncbi.nlm.nih.gov/35320390/

Follow-up cardiac magnetic resonance (CMR) in 7 children with Pfizer vaccine associated myocarditis: https://pubmed.ncbi.nlm.nih.gov/35482094/

Followup CMR imaging in 15 patients 6 months after Pfizer associated myocarditis: https://pubmed.ncbi.nlm.nih.gov/35320390/

2 cases of myocarditis presenting with ST segment elevation in adolescent males after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34180390/

Cardiac complications following mRNA vaccination: a systematic review of case reports and case series: https://pubmed.ncbi.nlm.nih.gov/34921468/

Myopericarditis following mRNA vaccination: the role of cardiac biomarkers and multimodality imaging: https://pubmed.ncbi.nlm.nih.gov/34487161/

Myocarditis should be consider in those with a troponin rise and unobstructed arteries following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34463755/

Miokarditis, povezan s cepljenjem proti COVID-19: izvidi ehokardiografije, tomografije srca in magnetne resonance: https://pubmed.ncbi.nlm.nih.gov/34428917/

Značilnosti srčne magnetne resonance akutnega miokarditisa, ki se pojavi po imunizaciji s cepivom mRNA: https://pubmed.ncbi.nlm.nih.gov/34787887/

Fulminantni miokarditis in sistemsko hipervnetje pri 2 bolnikih po mRNA: https://pubmed.ncbi.nlm.nih.gov/34416319/

2 primera histološko potrjenega miokarditisa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34407340/

Miokarditis in perikarditis: 2 poročila o primerih: https://pubmed.ncbi.nlm.nih.gov/34277198/

Dva primera miokarditisa https://pubmed.ncbi.nlm.nih.gov/34166884/

3 primeri srčne manifestacije po Pfizerju: https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcab177/6311674

4 primeri miokarditisa in njihovi izvidi MRI srca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245050/

4 primeri miokarditisa: https://pubmed.ncbi.nlm.nih.gov/34396358/

6 primerov moških, starih od 17 do 37 let, z miokarditisom: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219373/

8 primerov miokarditisa pri mladostnikih po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34319393/

13 primerov miokarditisa pri mladostnikih po Pfizerju: https://www.jpeds.com/article/S0022-3476(21)00665-X/fulltext

Pregled 15 objavljenih primerov miokarditisa: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272967/

Miokarditis in perikarditis zaradi mRNA cepiv v 19 primerih: https://pubmed.ncbi.nlm.nih.gov/34805376/

Miokarditis pri 23 pripadnikih vojske: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601

Pregled 29 objavljenih primerov akutnega mioperikarditisa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34356586/

Pregled 214 primerov miokarditisa: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233865/

 

kardiomiopatija:

Takotsubo kardiomiopatija, povezana s cepivom Covid-19: https://pubmed.ncbi.nlm.nih.gov/34375049/

63yoF with Takotsubo cardiomyopathy following Moderna: https://pubmed.ncbi.nlm.nih.gov/34330629/

Reverse takotsubo cardiomyopathy as a cause of acute chest pain in a young woman following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34961327/

Acute MI (Myocardial Infarction):

3 cases of acute infarct-like myocarditis (2 Pfizer, 1 AstraZeneca): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325525/ 

2 cases of acute MI <24 hours after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34364657/

Acute STEMI MI following AstraZeneca vaccination,?Kounis syndrome?:  https://pubmed.ncbi.nlm.nih.gov/34394944/

Vaccine induced immune thrombocytopenia and thrombosis associated anterior ST-elevation myocardial infarction following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34486030/

Hypertension:

Hypertension following mRNA vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206586/

POTS (Postural Orthostatic Tachycardia Syndrome):

5 cases of POTS following vaccination, age 17 and up: https://pubmed.ncbi.nlm.nih.gov/35870086/

Postural orthostatic tachycardia syndrome after mRNA COVID-19 vaccine: https://link.springer.com/article/10.1007/s10286-022-00880-3 https://pubmed.ncbi.nlm.nih.gov/35870086/

POTS following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33968543/ https://www.cureus.com/articles/56242-a-case-of-postural-orthostatic-tachycardia-syndrome-secondary-to-the-messenger-rna-covid-19-vaccine

Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine https://academic.oup.com/ehjcr/article/5/12/ytab472/6444985

 

Tachycardia:

Isolated tachycardia in a 29yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34466331/

Tachycardia following Pfizer: 3 cases in those previously infected with COVID-19: https://pubmed.ncbi.nlm.nih.gov/33858709/

 

Long QT / Conduction Disturbance:

VT storm in long QT resulting from COVID-19 vaccine allergy treated with epinephrine: https://pubmed.ncbi.nlm.nih.gov/34791122/

Long QT syndrome following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34804335/

Two cases of vaccine induced cardiac conduction disturbance following Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34796078/

Dizziness, HTN and new LBBB following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34508485/

Frequent PVS and NSVT following 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34275963/

Unmasked type 1 Brugada pattern without fever in a 32yoM following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776624/

 

drugo:

Posttransplantacijska limfoproliferativna motnja po uporabi zdravila AstraZeneca pri prejemniku srčnega presadka: https://pubmed.ncbi.nlm.nih.gov/34702598/

Prebavila:

Tveganje neželenih dogodkov in poročanje o ponovitvi bolezni po cepljenju proti COVID-19 pri bolnikih s KVČB: https://pubmed.ncbi.nlm.nih.gov/34819330/

13 let z adenomezenteritisom po 1. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/35883977/

Gastropareza:

Gastropareza po Pfizerju: https://journals.lww.com/ajg/Citation/9900/Gastroparesis_After_Pfizer_BioNTech_COVID_19.28.aspx

Trebušna slinavka:

14 let z akutnim pankreatitisom po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35081801/

17 let z akutnim pankreatitisom po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35053654/

71 let z akutnim pankreatitisom po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35029194/

Poškodba pankreatitisa po Pfizerju, prikaz primera: https://pubmed.ncbi.nlm.nih.gov/34205898/

Akutni nekrotizirajoči pankreatitis po 2. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/34423463/

Akutni pankreatitis pri 96 let po 1. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/34084669/

Zavrnitev alogenskega presadka trebušne slinavke po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34781027/

 

Hepatitis:

Cutaneous hypersensitivity reaction with acute hepatitis following Pfizer 2nd dose: https://pubmed.ncbi.nlm.nih.gov/34485657/

35yoF third month post partum with autoimmune hepatitis following vaccination: https://pubmed.ncbi.nlm.nih.gov/33862041/

Liver transplant in a 53yo healthy man due to vaccine induced autoimmune hepatitis and subsequent liver failure following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/35175635/

65yoM with autoimmune hepatitis following Moderna: https://pubmed.ncbi.nlm.nih.gov/34717185/

79yoM with AstraZeneca induced autoimmune hepatitis: https://pubmed.ncbi.nlm.nih.gov/35013724/

Three cases of autoimmune hepatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34904265/

A case of hepatotoxicity in 14yoF after receiving Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/35070524/

Post-transplant autoimmune recurrence following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/35390478/

27yoF with autoimmune hepatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35437965/

82yoF with history of HCV treatment with autoimmune hepatitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35716255/

Development of hepatitis and colitis in a 52yoF with cancer during immunotherapy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35694999/

Severe de novo liver injury after Moderna vaccination-not always autoimmune hepatitis: https://pubmed.ncbi.nlm.nih.gov/35439566/

Liver injury and cytopenia in an adolescent following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35510521/

Clinical significance of hepatosplenic thrombosis in VITT after AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34958931/

AMA-positive hepatitis in a 56yoF induced by Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/35040333/

Hepatic artery occlusion following Astrazeneca: https://pubmed.ncbi.nlm.nih.gov/34926142/

Acute cholestatic hepatitis after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34256064/

52yoF with autoimmune hepatitis following Moderna: https://onlinelibrary.wiley.com/doi/10.1111/liv.15092

41yo F with Autoimmune hepatitis following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197609/

76yoF with autoimmune hepatitis following Moderna Vaccination: https://pubmed.ncbi.nlm.nih.gov/34332438/

71yoF with Autoimmune hepatitis after mRNA vaccine (Moderna): https://www.sciencedirect.com/science/article/pii/S0168827821018961?via%3Dihub

80yoF with autoimmune hepatitis following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186938/

63yoM with autoimmune hepatitis following Moderna: https://pubmed.ncbi.nlm.nih.gov/34293683/

61yoF with liver injury following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34430106/

61yoF with autoimmune hepatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34781161/

35yoF with autoimmune hepatitis following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/

New Onset autoimmune hepatitis following mRNA vaccination in a 36yoF with Primary sclerosing cholangitis:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384483/

56yoF with autoimmune hepatitis following Moderna: https://www.journal-of-hepatology.eu/article/S0168-8278(21)00424-4/fulltext

Two cases of autoimmune hepatitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34225251/

Poškodba jeter pri bolniku s presaditvijo jeter po cepljenju z mRNA: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214934/

16 primerov poškodb jeter po Pfizerju in Moderni: večcentrična serija primerov: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324396/

Ponovna aktivacija okužbe s hepatitisom C po Pfizerju v 82yoF: https://www.dovepress.com/hepatitis-c-virus-reactivation-following-covid-19-vaccination–a-case–peer-reviewed-fulltext-article-IMCRJ ?fbclid=IwAR3u0x1baFcAZz1eOrNsXsgmrlUYt0EJV2SmoXA75RiplFQbPrtSAIO2GAs

 

drugo:

Vnetna črevesna bolezen, ki jo sproži cepivo Pfizer: https://pubmed.ncbi.nlm.nih.gov/34922342/

De Novo pediatrični ulcerozni kolitis sproži Pfizer: zgodba o 2 sestrah: https://pubmed.ncbi.nlm.nih.gov/35762665/

Ishemični kolitis pri 48yF po 2. odmerku inaktiviranega cepiva covid019: https://pubmed.ncbi.nlm.nih.gov/35647139/

Sklerozirajoči holangitis: https://pubmed.ncbi.nlm.nih.gov/34450237/

Nenavadna vročina, HA in bolečine v trebuhu pri zdravi ženski po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34339677/

Tromboza jetrne vene zaradi TTS po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34432063/

3 primeri tromboze portalne vene po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34776709/

 

Ledvična:

ANCA:

Glomerulonefritis ANCA po Moderni: https://www.kidney-international.org/article/S0085-2538(21)00555-X/fulltext

Prikaz primera: vaskulitis ANCA z akutno odpovedjo ledvic in pljučno krvavitvijo po Moderni: https://pubmed.ncbi.nlm.nih.gov/34859017/

Nov pojav vaskulitisa ANCA po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34280507/

Glomerulonefritis, povezan z ANCA po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34423176/

Vaskulitis, povezan z ANCA, ki se kaže z rabdomiolizo in pauciimunskim polmesečastim glomerulonefritisom po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34659268/

Anti-GBM nefritis z mezangialnimi depoziti IgA po Moderni: https://pubmed.ncbi.nlm.nih.gov/34119511/

Sočasni nefritis antiglomerularne bazalne membrane (Anti-GBM) in glomerulonefritis ANCA pri 23-letniku po 2. odmerku zdravila Moderna: https://pubmed.ncbi.nlm.nih.gov/34746518/

Two adolescent cases of acute tubulointerstitial nephritis after 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35385678/

58yoF with Pfizer induced severe rhabdomyolysis with acute AKI requiring renal replacement therapy: https://pubmed.ncbi.nlm.nih.gov/35747054/

De novo and relapsing necrotizing vasculitis after mRNA vaccination, 5 cases: 4 cases of relapsing ANCA vasculitis and 1 de novo polyarteritis nodosa: https://pubmed.ncbi.nlm.nih.gov/35211310/

COVID-19 vaccination precipitating de novo ANCA associated vasculitis: clinical implications: https://pubmed.ncbi.nlm.nih.gov/35498903/

PTU-induced ANCA-associated vasculitis after Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/

Relapsed ANCA associated vasculitis following AstraZeneca: A case series of two patients: https://pubmed.ncbi.nlm.nih.gov/34755433/

ANCA associated vasculitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416184/

 

Nephrotic Syndrome:

Relapse of idiopathic nephrotic syndrome following COVID-19 vaccination in a 17yoF: https://pubmed.ncbi.nlm.nih.gov/35416332/

Idiopathic nephrotic syndrome relapse following covid-19 vaccination, a series of 25 cases, age 16 and up:https://pubmed.ncbi.nlm.nih.gov/35979142/

IgA nephropathy in a 13yoF and 16yoM following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35352188/

Nephrotic Syndrome following AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257404/

New onset pediatric nephrotic syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34782983/

Nephrotic syndrome and vasculitis following Pfizer, Moderna, and AstraZeneca: https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfab215/6318785

 

Minimal Change Disease:

MCD relapse following Pfizer in a man in his mid-60s: https://pubmed.ncbi.nlm.nih.gov/34023417/

MCD relapse following Pfizer in a 34yoF: https://pubmed.ncbi.nlm.nih.gov/33964312/

Severe Minimal change disease relapse 3 days following Pfizer: https://europepmc.org/article/pmc/pmc8156905

Minimal Change Disease with nephrotic syndrome and AKI following Pfizer in a 50yoM: https://pubmed.ncbi.nlm.nih.gov/33839200

Minimal change disease in a 18yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35611026/

Minimal change disease in a 25yoF following 1st dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35435622/

Minimal change disease following Pfizer in a living kidney donor: https://pubmed.ncbi.nlm.nih.gov/35056345/

2 cases of nephrotic syndrome with minimal change disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35246429/

Minimal change disease in 80’s yoM following first dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/33992727/

Minimal change disease after 1st dose Pfizer 60yoM: https://pubmed.ncbi.nlm.nih.gov/34804557/

Minimal change disease and AKI in a 77yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34000278/

Bolezen z minimalnimi spremembami 4 dni po Pfizerju pri 45 let starosti: https://pubmed.ncbi.nlm.nih.gov/34721864/

Bolezen z minimalnimi spremembami pri 39-letniku po 1. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/34143368/

Bolezen z minimalnimi spremembami pri 63-letniku, ki sledi Moderni: https://pubmed.ncbi.nlm.nih.gov/34048824/

Bolezen minimalnih sprememb pri 43-letniku, ki sledi Moderni: https://pubmed.ncbi.nlm.nih.gov/34052236/

Ponovitev bolezni minimalnih sprememb s hudim nefrotskim sindromom pri 22-letniku po Moderni: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156905/

Bolezen minimalne spremembe in huda AKI po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34242687/

Ponovitev bolezni minimalne spremembe pri 30-letniku, ki je prejemal zdravilo AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34119512/

Nov pojav nefrotičnega sindroma zaradi bolezni minimalne spremembe po J&J: https://pubmed.ncbi.nlm.nih.gov/34342187/

2 primera bolezni z minimalnimi spremembami po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34779088/

3 primeri bolezni z minimalnimi spremembami po 2. odmerku mRNA cepiva: https://pubmed.ncbi.nlm.nih.gov/34337193/

13 primerov nove ali ponavljajoče se bolezni minimalne spremembe po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34632166/

 

Nefropatija / IGA vaskulitis:

Akutni intersticijski nefritis po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35113012/

Sorodniški primeri nefropatije IgA (15 let in 18 let) po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35729514/

IgA nefropatija pri 12-letniku po 1. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/35339305/

Ponovni pojav IgA nefropatije pri 54 let starosti po 2. odmerku zdravila Moderna: https://pubmed.ncbi.nlm.nih.gov/35392838/

2 primera makroskopske hematurije pri otrocih z remisijo IgA nefropatije po Pfizerju (15 let, 16 let): https://pubmed.ncbi.nlm.nih.gov/35301586/

2 primera (19 let M, 50 let Ž), histološki korelati velike hematurije po Moderni pri bolnikih z nefropatijo IgA (ponovitev bolezni po cepljenju): https://pubmed.ncbi.nlm.nih.gov/34146600/

Akutna T-celica posredovana zavrnitev po Pfizerju pri prejemniku presajene ledvice: https://pubmed.ncbi.nlm.nih.gov/35769849/

Nenadno poslabšanje okultne IgA nefropatije po prvem odmerku Pfizerja pri Japonki v 40-ih: https://pubmed.ncbi.nlm.nih.gov/34988883/

Razvoj vaskulitisa IgA s hudim glomerulonefritisom po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35275366/

New onset kidney biopsy proven IgA vasculitis in a 47yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/35075622/

2 cases of IgA vasculitis following Pfizer (22yoM and 30yoM): https://pubmed.ncbi.nlm.nih.gov/35253880/

19 cases of IgA vasculitis post COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35229346/

Acute interstitial nephritis in a 63yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35254639/

2 cases of acute interstitial nephritis with concurrent nephrotic syndrome  (69yoF and 60yoF) following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35211313/

New-onset kidney diseases after COVID-19 vaccination: a case series (5 patients): https://pubmed.ncbi.nlm.nih.gov/35214760/

Glomerular disease in temporal association with COVID-19 vaccination: a series of 29 cases: https://pubmed.ncbi.nlm.nih.gov/35372991/

New onset biopsy proven nephropathies after COVID vaccination, 17 patients: https://pubmed.ncbi.nlm.nih.gov/35354140/

New-onset and relapse of nephrotic syndrome following COVID-19 vaccination, 27 patients in Japan, a questionnaire survey: https://pubmed.ncbi.nlm.nih.gov/35569069/

Clinical spectrum of gross haematuria following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35498904/

Atypical haemolytic uraemic syndrome following Pfizer in a 60yoF: https://pubmed.ncbi.nlm.nih.gov/35756730/

A case of acute interstitial nephritis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34219853/

Acute interstitial nephritis in a 45yoF following 2 doses of Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650829/

Isolated renal arteritis with infarction after Pfizer COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35095058/

13 cases of new or relapsed glomerulonephritis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34632166/

48 cases of new onset and relapsed kidney histopathology following COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622870/

New onset lupus in a 68yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35294664/

New onset of Class III lupus nephritis with multi-organ involvement after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35108572/

IgA nephropathy presenting as rapidly progressive glomerulonephritis in a 13yo following 1st dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34786589/

IgA and crescentic glomerulonephritis following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141343/

17yoM with newly diagnosed IgA nephropathy with gross hematuria following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34865167/

17yoF with IgA nephropathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35118635/

IgA nephropathy in a 28yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35110484/

28yoF with flare up of IgA nephropathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35108771/

29yoF with hematuria and likely IgA nephritis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35102819/

Nefropatija IgA izbruhne po Moderni: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079938/

Nefropatija IgA po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34278290/

Izbruh nefropatije IgA po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34415336/

IgA nefropatija po cepljenju pri prejemniku ledvičnega presadka z anamnezo nefropatije aristolohične kisline: https://pubmed.ncbi.nlm.nih.gov/34816609/

IgA nefropatija pri 2 pediatričnih bolnikih po Pfizerju (13 in 17 let): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256683/

3 primeri bolnikov z nefropatijo IgA, pri katerih so se po cepivu mRNA pojavila poslabšanja: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166778/

2 primera bolnikov z nefropatijo IgA, pri katerih so se pojavila poslabšanja po Moderni: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987498/

2 primera bolnikov z nefropatijo IgA, ki so po Pfizerju razvili hematurijo: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329426/

Ponovna aktivacija vaskulitisa IgA po Moderni: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260100/

Ponovna aktivacija vaskulitisa IgA po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34848431/

Primer vaskulitisa IgA po cepljenju Pfizer: https://pubmed.ncbi.nlm.nih.gov/34535924/

IgA vaskulitis po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34509658/

IgA vaskulitis s prizadetostjo ledvic in kože po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34779011/

Membranozna nefropatija po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34419553/

Membranozna nefropatija po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34332960/

 

drugo:

Izrazita hematurija po cepljenju z mRNA pri dveh bolnikih s histološko in klinično diagnozo nefropatije IgA: https://pubmed.ncbi.nlm.nih.gov/34766415/

Huda hematurija po cepljenju Moderna proti COVID pri 2 bolnikih z nefropatijo IgA: https://pubmed.ncbi.nlm.nih.gov/33771584/

Izrazita glomerularna bolezen po cepljenju z mRNA: analiza Vigibase: https://pubmed.ncbi.nlm.nih.gov/34822875/

Ledvična trombotična mikroangiopatija po Pfizerju pri 35-letnem bolniku: https://pubmed.ncbi.nlm.nih.gov/34451509/

Glomerulopatije po cepljenju proti covidu-19: štirje primeri s tremi različnimi cepivi v Argentini: https://pubmed.ncbi.nlm.nih.gov/34728874/

Rheumatology/Endocrinology/Orthopedics:

General:

Cutaneous lupus erythematosus-like reaction following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35754159/

Hyper-inflammation after COVID-19 mRNA vaccination: at the cross roads of multi-inflammatory disease and adult onset still’s disease https://pubmed.ncbi.nlm.nih.gov/34487678/

Immune mediated disease flares: https://pubmed.ncbi.nlm.nih.gov/33946748/

Local and systemic reactogenicity of Pfizer in patients with systemic lupus and rheumatoid arthritis: https://pubmed.ncbi.nlm.nih.gov/34476603/

Incidence of disease flare after Pfizer vaccination in patients with rheumatoid arthritis in remission: https://pubmed.ncbi.nlm.nih.gov/34472714/

11% of patients with rheumatic and MSK diseases report disease flare following 2 dose mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34346185/

Macrophage Activation Syndrome:

Macrophage activation syndrome in a patient with adult-onset Still’s disease following first dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34961551/

 

Still’s Disease:

Adult onset Still’s disease following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34316728/

Adult onset Still’s disease after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35186544/

Flare up of adult onset Still’s disease in a 37yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34622765/

Stillova bolezen v odrasli dobi pri 43-letniku, ki je spremljal Pfizer: https://pubmed.ncbi.nlm.nih.gov/34763089/

Izbruh bolezni, ki se pojavi pri odraslih, po Pfizerju pri 49 let starosti: https://pubmed.ncbi.nlm.nih.gov/35182269/

Stillova bolezen pri 34 let po cepljenju z AstraZeneco: https://pubmed.ncbi.nlm.nih.gov/34797392/

Stillova bolezen v odrasli dobi pri 36-letniku, ki spremlja Pfizer: https://pubmed.ncbi.nlm.nih.gov/34962116/

Stillova bolezen pri odraslih po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34316726/

 

Lupus:

Nov pojav sistemskega eritematoznega lupusa, ki se začne kot lupusni nefritis razreda V po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34560139/

Izbruh lupusnega nefritisa po Moderni: https://pubmed.ncbi.nlm.nih.gov/34791449/

Poslabšanje lupusa: https://onlinelibrary.wiley.com/doi/10.1111/dth.15017

Novonastali sistemski eritematozni lupus po AstraZeneci in alopecija areata po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35770484/

Poslabšanje lupusa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34291477/

27 primerov izbruha lupusa po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34782941/

Nov pojav lupusa po cepljenju z mRNA pri 27 letih: https://pubmed.ncbi.nlm.nih.gov/35186342/

Sistemski lupus po cepljenju z AstraZeneco: https://pubmed.ncbi.nlm.nih.gov/34418261/

Ponovitev lupusa razreda V. Nefritis po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34352310/

Subakutni kožni izbruh eritematoznega lupusa, ki ga sproži Moderna: https://pubmed.ncbi.nlm.nih.gov/34455671/

Subakutni kožni eritematozni lupus po Pfizerju pri ženski s primarnim žolčnim holangitisom: https://pubmed.ncbi.nlm.nih.gov/34807495/

Nov pojav lupusa, pankreatitisa in vaskulitičnega izpuščaja pri 22-letnem bolniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35175446/

Pojav novega pojava SLE po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34450645/

 

Hiperglikemični / glukoza:

Cepivo proti COVID-19 in hiperosmolarno hiperglikemično stanje: https://pubmed.ncbi.nlm.nih.gov/33927933/

Akutna hiperglikemična kriza: serija primerov 3 bolnikov, ki so jemali zdravilo AstraZeneca: https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.14631

Na novo razvita sladkorna bolezen tipa 1 po Moderni pri 73yoF: https://pubmed.ncbi.nlm.nih.gov/35088548/

3 primeri poslabšanja hiperglikemije pri bolnikih s sladkorno boleznijo tipa 2 po AstraZeneci: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143905/

3 primeri nujnih hiperglikemičnih stanj po Pfizerju in Moderni: https://pubmed.ncbi.nlm.nih.gov/34604689/

Motnje glukoze v krvi po cepljenju, pregled 20 odraslih: https://pubmed.ncbi.nlm.nih.gov/34375490/

Hipertrigliceridemija po cepljenju s Pfizerjem pri bolniku z družinsko hiperholesterolemijo: https://pubmed.ncbi.nlm.nih.gov/34533798/

 

Ščitnica:

Tihi tiroiditis po Pfizerju, subakutni tiroiditis po Moderni in Gravesova bolezen po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34792795/

Subakutni tiroiditis po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/35095149/

SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review: https://pubmed.ncbi.nlm.nih.gov/35094372/

11 cases of COVID-19 vaccine induced subacute thyroiditis: https://pubmed.ncbi.nlm.nih.gov/35182366/

 

Subacute Thyroiditis: 

https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.1947102?fbclid=IwAR02FYW94iQGbu6e2uTpD42XoIwp6QHzwhDBWotULtT4ZCGR5sVKkyexbRg

Subacute thyroiditis following vaccination: https://pubmed.ncbi.nlm.nih.gov/34690055/

Subacute thyroiditis following Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34777881/

Subacute thyroiditis following Pfizer: a tale of two sisters: https://pubmed.ncbi.nlm.nih.gov/34686971/

Subacute thyroiditis associated thyrotoxic periodic paralysis in a 26yoF following 2nd dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35578985/

42yoF with subacute thyroiditis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34907904/

Thyroiditis after mRNA vaccine: a case series: https://pubmed.ncbi.nlm.nih.gov/34934810/

Two cases of subacute thyroiditis after Moderna and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34504856/

4 cases of subacute thyroiditis after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34893014/

Two cases of thyroiditis after Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34693241/

New onset Graves disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34888290/

Graves disease following 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34969799/

Graves disease following mRNA COVID-19 vaccination: case series: https://pubmed.ncbi.nlm.nih.gov/34939881/

New onset Graves disease and autoimmune diabetes mellitus following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34653776/

Two cases of Graves disease following vaccination: https://pubmed.ncbi.nlm.nih.gov/33858208/

Two more cases of Graves disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34342859/

Hyperthyroidism following vaccination: https://pubmed.ncbi.nlm.nih.gov/34696214

Incidental findings on a TC99M-SESTAMIBI parathyroid scan post Moderna vaccination in a 48yoF: https://pubmed.ncbi.nlm.nih.gov/35535123/

 

Adrenal:

5 cases of adrenal crisis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34358373/

Myositis in a 56yoF following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/33647971/

COVID-19 vaccine induced cellulitis and myositis: https://pubmed.ncbi.nlm.nih.gov/34857596/

New onset giant cell arteritis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35112193/

2 cases of Löfgren’s syndrome following AstraZeneca and Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34835244/

mRNA induced rhabdomyolysis and fasciitis: https://pubmed.ncbi.nlm.nih.gov/34435250/

Rabdomioliza po Moderni: https://pubmed.ncbi.nlm.nih.gov/34150372/

21 let z rabdomiolizo, ki jo je povzročil Pfizer: https://pubmed.ncbi.nlm.nih.gov/34186348/

 

Vnetje/artritis:

Spekter kratkotrajnih vnetnih mišično-skeletnih manifestacij po dajanju cepiva proti COVID-19: poročilo o 66 primerih: https://pubmed.ncbi.nlm.nih.gov/34836886/

Sindrom kubitalnega kanala, začasno po Moderni v 28 letih: https://pubmed.ncbi.nlm.nih.gov/35448837/

Novonastala revmatska polimialgija pri 80-letnem bolniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34897152/

Revmatska polimialgija po cepljenju proti covidu-19: serija primerov desetih bolnikov: https://pubmed.ncbi.nlm.nih.gov/34954076/

Ponovitev revmatične polimialgije pri 83-letniku: https://pubmed.ncbi.nlm.nih.gov/33588357/

2 primera revmatične polimialgije in 1 primer gigantoceličnega arteritisa po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34600148/

50 let s kliničnim sindromom HSP, vključno z IgA levkocitoklastičnim vaskulitisom na kožni biopsiji po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34984055/

Vnetje regije štirikotnega prostora in druge naključne ugotovitve na MRI rame po cepljenju Pfizer proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34306275/

Izpuščaj, artritis, oteklina, mišična oslabelost po zdravilu AstraZeneca: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.27175

Samoomejujoča polimialgija revmatskemu podobnemu sindromu po cepljenju Moderna: https://pubmed.ncbi.nlm.nih.gov/34980802/

Sindrom poliartralgije in mialgije po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34463066/

Huda poliartralgija pri starejših ženskah po zdravljenju z zdravilom AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34835151/

Artritis L komolca po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34363344/

Vaskulitis in burzitis na 18F FDG-PET/CT po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34495381/

Remitentni seronegativni simetrični sinovitis z luknjastim edemom po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34348912/

COVID-19 vaccination and large0vessel giant cell arteritis: https://pubmed.ncbi.nlm.nih.gov/34788208/

 

HSP:

11yoF with HSP following 1st dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/36056360/

40yoF with Henoch-Schonlein Purpura (HSP) following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34247902/

45yoF with reactivation of HSP following Pfizer booster: https://pubmed.ncbi.nlm.nih.gov/34745629/

62yo with HSP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34518812/

76yoF with HSP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34696186/

 

Psoriasis:

New onset mainly guttate psoriasis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34309932/

2 cases of exacerbation of plaque psoriasis after Pfizer and CoronaVac: https://pubmed.ncbi.nlm.nih.gov/34427024/

Psoriatic spondyloarthritis exacerbation triggered by mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/35176180/

Psorasis exacerbation in a 46yoM after 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/34131967/

14 cases of psoriasis activation following vaccination (Moderna, Pfizer, and AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34363647/

Pustuluar psoriasis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34398977/

Psorasis exacerbation after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34487570/

Scleroderma renal crisis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34339745/

Cryoglobulinaemia:

Flares of mixed cryoglobulineamia vasculitis after vaccination https://ard.bmj.com/content/early/2021/11/23/annrheumdis-2021-221248.long

Pheochromocytoma crisis following J&J vaccination: https://pubmed.ncbi.nlm.nih.gov/34707965/

 

Hematology

Treatment Guide to Thrombotic Thrombocytopenia Following Vaccination: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia

Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? https://pubmed.ncbi.nlm.nih.gov/35378658/

Successful venous thromboprophylaxis in a patient with AstraZeneca induced VITT: https://pubmed.ncbi.nlm.nih.gov/34496889/

Coagulopathies after vaccination against SARS-COV-2 may be derived from a combo of spike protein and adenovirus vector-triggered signaling pathways: https://arxiv.org/abs/2109.00089?fbclid=IwAR2orycgbxqSNXLR9A4XjNwEAZBumiRbRKsfW8KL5qiJCXSWwqmLiMtc4Z4

Arterijska tromboza na nenavadnem mestu (ulnarna arterija) pri 68-letniku po 3. odmerku Moderne: https://pubmed.ncbi.nlm.nih.gov/35645305/

Avtoimunski vzroki trombotičnih dogodkov po cepljenju proti COVID: https://pubmed.ncbi.nlm.nih.gov/34508917/

Tromboza po cepljenju proti COVID-19: možna povezava s potmi ACE: https://pubmed.ncbi.nlm.nih.gov/34479129/

Spremembe viskoznosti krvi po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34868465/

Aktivacija in modulacija trombocitov pri trombozi s trombocitopeničnim sindromom, povezana z zdravilom AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34474550

Znane znane in znane neznanke trombotične trombocitopenije, ki jo povzroča cepivo: https://pubmed.ncbi.nlm.nih.gov/34472568/

Življenjske posledice imunsko posredovane tromboze s trombocitopenijo, ki jo povzroči cepivo: https://pubmed.ncbi.nlm.nih.gov/34961923/

Koagulopatije po cepljenju proti SARS-COV-2 lahko izhajajo iz kombinacije signalnih poti, ki jih sprožijo vektorji spike proteina in adenovirusa: https://arxiv.org/abs/2109.00089?fbclid=IwAR2orycgbxqSNXLR9A4XjNwEAZBumiRbRKsfW8KL5qiJCXSWwqmLiMtc4Z4

Trombocitopenija in tromboza, povzročena s cepivom: venska endoteliopatija, ki vodi v kombinirano vensko mikro-makrotrombozo: https://pubmed.ncbi.nlm.nih.gov/34833382/

Vloge trombocitov pri koagulopatiji, povezani s COVID-19, in s cepivom povzročeni imunski trombotični trombocitopeniji: https://pubmed.ncbi.nlm.nih.gov/34455073/

Varnostno opozorilo za zdravilo AstraZeneca pri bolnikih s srpastocelično anemijo: https://mjhid.org/index.php/mjhid/article/view/4708?fbclid=IwAR2kMtsqqwiYyxxQ9XxIvDFdOSt-yTPqjAro-fgaEp460JeHd0QwBxx4DPg

 

hemoliza

Akutna hemoliza po cepljenju proti COVID-u pri starejšem moškem: https://pubmed.ncbi.nlm.nih.gov/34821933/

Avtoimunska hemolitična anemija: https://pubmed.ncbi.nlm.nih.gov/34150386/

Prvi in ​​smrtni primer avtoimunsko pridobljenega pomanjkanja faktorja XIII/13 po Pfizerju pri 78yoF: https://pubmed.ncbi.nlm.nih.gov/34856014/

Avtoimunska hemolitična anemija po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34258873/

Avtoimunska hemolitična anemija po Moderni z neodkrito perniciozno anemijo: https://pubmed.ncbi.nlm.nih.gov/35103106/

Hladna aglutininska bolezen pri 45-letnem bolniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34176130/

Hemolitična kriza pri ženski s hladno aglutininsko boleznijo po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/33939851/

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor following Moderna: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26262

6 Paraoxysmal nocturnal hemoglobinuria patients with hemolytic crisis following Pfizer and Moderna: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in

 

Anemia

Aplastic anemia in a 56yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34920343/

Aplastic anemia after COVID vaccination: https://pubmed.ncbi.nlm.nih.gov/34783367/

 

ITP

ITP and AIHA following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274740/

95yoM with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35022338/

2 cases of ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35022337/

ITP Exacerbation in previous stable patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34307734/

ITP relapse post-Pfizer vaccine in a 28yoM: https://pubmed.ncbi.nlm.nih.gov/34804803/

ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34155844/

ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34382388/

ITP following booster dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34820240

ITP in a man in his mid 20s following Pfizer requiring splenectomy: https://pubmed.ncbi.nlm.nih.gov/35725277/

38yoF with ITP and myocarditis following Moderna: https://pubmed.ncbi.nlm.nih.gov/35638196/

Exacerbation of ITP following initial and booster dose of Pfizer, 93 patients: https://pubmed.ncbi.nlm.nih.gov/35536172/

Secondary ITP and resulting hemorrhage and hematoma after minor oral surgery after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34314875/

ITP and diffuse papular rash following Moderna: https://www.scienceopen.com/document_file/691feaa0-8e64-40c4-9553-40382bd5ac48/PubMedCentral/691feaa0-8e64-40c4-9553-40382bd5ac48.pdf

ITP following Astrazeneca:  https://ashpublications.org/blood/article/doi/10.1182/blood.2021012790/476455/Immune-Thrombocytopenic-Purpura-after-vaccination

ITP in 1st trimester of pregnancy 13 days following vaccination in the US:  https://pubmed.ncbi.nlm.nih.gov/34420249/

20yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34381692/

22yoM with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33476455/

24yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34754937/

25yoF with ITP exacerbation following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34660131/

26yoF with ITP and acute liver injury following Moderna: https://pubmed.ncbi.nlm.nih.gov/34330722/

26yoF z ITP sledi Moderni: http://pubs.sciepub.com/ajmcr/9/8/3/index.html

28 let z ITP po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/33934330/

37 let z ITP po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34732627/

39 let z ITP po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34285180/

41 let s sekundarno ITP po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34059544/

41 let z ITP po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34377889/

54 let z ITP po Pfizerju: https://www.cureus.com/articles/56899-newly-diagnosed-idiopathic-thrombocytopenia-post-covid-19-vaccine-administration

63 let z ITP po Johnsonu in Johnsonu: https://pubmed.ncbi.nlm.nih.gov/34469919/

67 let z ITP po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34513446/

68 let z ITP v Koreji po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34751013/

68 let z ITP po Moderni: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385179/

69 let z refraktorno ITP po Pfizerju: https://journals.lww.com/americantherapeutics/Citation/2021/08000/Immune_Thrombocytopenic_Purpura_Associated_With.24.aspx

74yoM z ITP po Moderni: https://www.dovepress.com/severe-refractory-immune-thrombocytopenia-occurring-after-sars-cov-2-v-peer-reviewed-fulltext-article-JBM

84 let z ITP po Pfizerju: https://link.springer.com/article/10.1007/s11739-021-02778-w

86 let z ITP po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34446449/

2 primera ITP po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34114220/

3 primeri ITP po Pfizerju in Astra Zeneci: https://www.mjhid.org/index.php/mjhid/article/view/4669/4

3 poročila o primerih ITP po Pfizerju in J&J: https://ehoonline.biomedcentral.com/articles/10.1186/s40164-021-00235-0

57 let z miokarditisom in hipokaliemijo po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35430104/

74yoM with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34077572/

Acquired hemophilia A in a 39yoF following 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35211227/

69yoM with acquired hemophilia A after 2nd dose COVID vaccination: https://pubmed.ncbi.nlm.nih.gov/33783953/

Acquired hemophilia A in a 72yoM and concurrent diagnosis of pleomorphic dermal sarcoma following Moderna booster: https://pubmed.ncbi.nlm.nih.gov/35479071/

Acquired hemophilia A in a 72yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35379010/

Acquired hemophilia A and bullous pemphigoid in a 77yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/35321820/

Acquired hemophilia A in a man in his 80s after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35264381/

Acquired hemophilia A following Pfizer, successfully treated with prednisolone and rituximab: https://pubmed.ncbi.nlm.nih.gov/35088622/

4 cases of acquired hemophilia A after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35081484/

3 cases: recurrent AvWD and acquired hemophilia A after Moderna, PNH flare following Moderna, and ITP flare following Moderna: https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic

3 cases of acquired hemophilia A after mRNA vaccine, investigation into possible mechanism: https://pubmed.ncbi.nlm.nih.gov/35108443/

3 cases of ITP, 2 in chronic individuals and 1 in a healthy individual, following Pfizer and Moderna: https://pubmed.ncbi.nlm.nih.gov/34716890/

10 cases of ITP following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35108113/

3 cases of ITP in elderly patients following vaccination: https://www.hindawi.com/journals/crihem/2016/7913092/

4 cases of severe ITP following Pfizer, Moderna, and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34653943/

20 cases of ITP following Pfizer and Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/33606296/

21 cases of ITP following Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34756770/

36 Cases of ITP following Pfizer and Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011062/

77 denovo cases of ITP and 19 ITP exacerbation following vaccination: https://pubmed.ncbi.nlm.nih.gov/34587251/

12% of chronic ITP patients have exacerbation of ITP in 2-5 days following vaccination: https://pubmed.ncbi.nlm.nih.gov/34075578/

Thrombolytic / Thrombocytopenia

CoV-2 vaccination in patients with autoimmune cytopenias: the experience of a reference center: https://pubmed.ncbi.nlm.nih.gov/34478178/

PE, TIA, and thrombocytopenia after J&J: https://pubmed.ncbi.nlm.nih.gov/34261635/

Superior ophthalmic Vein Thrombosis and Thrombocytopenia following AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265377/

DVT and PE and positive HIT panel following mRNA Vaccine: https://pubmed.ncbi.nlm.nih.gov/34117206/

An unusual presentation of acute DVT after moderna vaccine: https://pubmed.ncbi.nlm.nih.gov/34790811/

3 patients with venous thromboembolism following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/

Tromboza s trombocitopenijo po Moderni: https://www.acpjournals.org/doi/full/10.7326/L21-0244

34 let s trombotično trombocitopenijo zaradi cepiva po Moderni: https://pubmed.ncbi.nlm.nih.gov/34804389/

Trombotična trombocitopenija po cepljenju s Pfizerjem pri japonskem bolniku: https://pubmed.ncbi.nlm.nih.gov/34803105/

Prikaz primera: s cepivom povzročena imunska trombotična trombocitopenija pri bolniku z rakom trebušne slinavke po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34790684/

Študija primera tromboze in trombocitopenije po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34781321/

Eltromopag za imunsko trombotično trombocitopenijo, povzročeno s cepivom, pri 64 let starosti po cepljenju z zdravilom AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34797474/

TTP po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34264514/

Pridobljen TTP po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34309715/

TTP v 25-letniki, ki sledi Moderni: https://pubmed.ncbi.nlm.nih.gov/34895163/

Klinična ponovitev imunsko pogojene TTP pri 28yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35155977/

Epizoda Denovo iTTP v 38yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34105244/

Pridobljen TTP v 61-letni osebi, ki spremlja Pfizer: https://pubmed.ncbi.nlm.nih.gov/34909764/

Serija primerov bolnikov, pri katerih se je v nekaj dneh po Pfizerju razvila pridobljena TTP: https://pubmed.ncbi.nlm.nih.gov/34909764/

TTP pri mladostniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34405400/

Izbruh kompenzirane prirojene TTP po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34693915/

Trombocitopenija pri najstniku s srpastocelično anemijo po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34331506/

5 primerov protrombotične imunske trombocitopenije po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34323939/

20 primerov trombocitopenije po Pfizerju in Moderni: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26132

Pregled 50 primerov trombocitopenije po Astrazeneca, Pfizer, Moderna: https://pubmed.ncbi.nlm.nih.gov/34332437/

68 let z obsežno trombozo po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34400433/

Trombotična trombocitopenija po AstraZeneci: Ugotovitve obdukcije: https://pubmed.ncbi.nlm.nih.gov/34355379/

3 primeri mladostnikov s TTP, ki ga je povzročil Pfizer: https://pubmed.ncbi.nlm.nih.gov/35373880/

Smrtni ICH zaradi trombotične trombocitopenije po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34402235/

Five cases with a combination of cerebral venous thrombosis, intracerebral hemorrhage and thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34393988/

 

VITT

Late Onset VITT with cerebral venous sinus thrombosis: https://pubmed.ncbi.nlm.nih.gov/35093626/

Confusion and abdominal pain due to VITT following vaccination: https://pubmed.ncbi.nlm.nih.gov/34346657/

Fatal thromboembolism in a patient with preexisting thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34344867/

Malignant CVA due to VITT following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34341358/

Anti-platelet factor 4 IgG levels in VITT: persistent positivity through 7 months: https://pubmed.ncbi.nlm.nih.gov/35515079/

Thrombosis patterns and clinical outcome of VITT: a systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/35339716/

Second dose VITT: rare but real: https://pubmed.ncbi.nlm.nih.gov/35482343/

Mechanisms of immunothrombosis in VITT compared to natural COVID infection: https://pubmed.ncbi.nlm.nih.gov/34051613/

3 cases of immune thrombocytopenia following AstraZeneca in Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/

 

Other:

New onset evans syndrome associated with systemic lupus erythematosus after Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34687421/

Skin, nose, and gingival bleeding episodes after AstraZeneca: a large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/

Haemophagocytosis and atypical lymphocytes on bone marrow biopsy following vaccination: https://pubmed.ncbi.nlm.nih.gov/34312842/

Hemophagocytic lymphohistiocytosis (HLH) in a 14yoF requiring VA ECMO: https://pubmed.ncbi.nlm.nih.gov/35455321/

3 cases of HLH following AstraZeneca: https://jcp.bmj.com/content/early/2021/07/22/jclinpath-2021-207760

Idiopathic ipsilateral external jugular vein thrombophlebitis after Pfizer vaccination:  https://pubmed.ncbi.nlm.nih.gov/33624509/

Possible risk of thrombotic events following AstraZeneca in women receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/

Blood clots and bleeding events following Pfizer and AstraZeneca: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with AstraZeneca in Denmark and Norway: a population based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/

Povezava AstraZenece in Pfizerja z večjimi venskimi, arterijskimi ali trombocitopeničnimi dogodki: populacijska kohortna študija 46 milijonov odraslih v Angliji: https://pubmed.ncbi.nlm.nih.gov/35192597/

Izolirana tromboza po cepljenju proti COVID-19: serija primerov: https://pubmed.ncbi.nlm.nih.gov/34993889/

Arterijska tromboza po 1. odmerku zdravila AstraZeneca: serija primerov: https://pubmed.ncbi.nlm.nih.gov/35571586/

Onkologija:

Splošno

Časovni presnovni odziv na cepljenja z mRNA pri onkoloških bolnikih: https://pubmed.ncbi.nlm.nih.gov/34463888/

Koordinacija in optimizacija FDG PET/CT in cepljenja; izkušnje, pridobljene v zgodnjih fazah množičnega cepljenja: https://pubmed.ncbi.nlm.nih.gov/34029956/

Limfadenopatija po cepljenju: poročilo o citoloških izvidih ​​aspiracijske biopsije s tanko iglo: https://pubmed.ncbi.nlm.nih.gov/34432391/

Aksilarna limfadenopatija po cepljenju pri ženski z rakom dojke: https://pubmed.ncbi.nlm.nih.gov/34940788/

Aspiracija s tanko iglo pri limfadenopatiji, povezani s cepivom: https://pubmed.ncbi.nlm.nih.gov/34286849/

Hipermetabolna limfadenopatija po Pfierju, incidenca ocenjena s FDG PET-CT in pomembnost za interpretacijo študije, pregled 728 cepljenih bolnikov: https://pubmed.ncbi.nlm.nih.gov/33774684/

 

Limfadenopatija/adenopatija:

Limfadenopatija po cepljenju: pregled rezultatov slikanja: https://pubmed.ncbi.nlm.nih.gov/33985872/

Aksilarna limfadenopatija po cepljenju z mRNA https://pubmed.ncbi.nlm.nih.gov/34156552/

Ipsilateralna aksilarna adenopatija po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34333959/

Globoka aksilarna limfadenopatija po cepljenju: prikaz primera: https://pubmed.ncbi.nlm.nih.gov/34694537/

Enostranska aksilarna limfadenopatija po cepljenju: prikaz primera in izvidi slikanja: https://pubmed.ncbi.nlm.nih.gov/33868525/

Enostranska aksilarna limfadenopatija po cepljenju: https://pubmed.ncbi.nlm.nih.gov/33617289/

Aksilarna adenopatija po cepljenju, nova diagnostična dilema: https://pubmed.ncbi.nlm.nih.gov/34825530/

Enostranska aksilarna adenopatija v okviru cepiva proti covidu-19: https://pubmed.ncbi.nlm.nih.gov/33486146/

Cepljenje proti COVID-19 (Pfizer), ki simulira napredovanje bezgavk pri bolniku z rakom prostate: https://pubmed.ncbi.nlm.nih.gov/35747740/

Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a Moderna vaccine recipient: https://pubmed.ncbi.nlm.nih.gov/35748061/

COVID-19 vaccine induced subclinical axillary lymphadenopathy on screening mammogram: https://pubmed.ncbi.nlm.nih.gov/34906409/

Unilateral axillary adenopathy following vaccination: a multimodality pictorial illustration and review of current guidelines: https://pubmed.ncbi.nlm.nih.gov/34053731/

False positive axillary lymph nodes on FDG PET/CT resulting from covid-19 immunization: https://pubmed.ncbi.nlm.nih.gov/33883486/

4 cases of axillary adenopathy following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34303188/

COVID-19 vaccination associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/

163 cases of axillary adenopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34257025/

mRNA vaccination: age and immune status and its association with axillar lymph node PET/CT uptake, a review of 426 patients: https://pubmed.ncbi.nlm.nih.gov/33893188/

Ipsilateral avid axillary lymph node update at FDG PET/CT persists in 29% of patients 7-10 weeks after 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/33904778/

Incidence of axillary adenopathy on Breast Imaging following Vaccination: https://pubmed.ncbi.nlm.nih.gov/34292295/

Breast radiation recall phenomena after AstraZeneca: A case series: https://pubmed.ncbi.nlm.nih.gov/35103229/

Regional lymphadenopathy following vaccination: literature review and considerations for patient management in breast cancer care: https://pubmed.ncbi.nlm.nih.gov/34731748/

Axillary lymphadenopathy at the time of vaccination: ten recommendations from the European society of breast imaging: https://pubmed.ncbi.nlm.nih.gov/34417642/

Evolving bilateral hypermetabolic axillary lymphadenopathy on FDG PET/CT following 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/

Axillary lymph nodes hypermetabolism after Pfizer in cancer patients underoing 18F-FDG PET/CT: a cohort study: https://pubmed.ncbi.nlm.nih.gov/33782299/

Reactive axillary lymphadenopathy to covid-19 vaccination on F-FDG PET/CT: https://pubmed.ncbi.nlm.nih.gov/33820864/

Association of COVID-19 mRNA vaccine with ipsilateral axillary node reactivity on imaging: https://pubmed.ncbi.nlm.nih.gov/34110378/

Supraclavicular lymphadenopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34414929/

Rare case of contralateral supraclavicular lymphadenopathy after vaccination: CT and ultrasound findings: https://pubmed.ncbi.nlm.nih.gov/34667486/

Supraclavicular lymphadenopathy after vaccination in Korea: a serial follow-up using ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/

Supraclavicular lymphadenopathy following vaccination: an increasing presentation to the two-week wait neck lump clinic? https://pubmed.ncbi.nlm.nih.gov/33685772/

Vaccination and low cervical lymphadenopathy in the two week neck lump clinic- a follow up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/

Cervical lymphadenopathy following Pfizer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204135/

13 primerov cervikalne limfadenopatije: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241354/

50M z adenopatijo po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34406229/

Pregled 24 primerov limfadenopatije in njihovih ultrazvočnih izvidov v ZDA: https://pubmed.ncbi.nlm.nih.gov/34356507/

Bolezen Kikucki-Fujimoto po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34395192/

2 primera bolezni Kikuchi-Fujimoto po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34835182/

Mamografski in sonografski izvidi dojke in aksilarnega repa po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34340203/

Zdravljenje enostranske aksilarne limfadenopatije, odkrite na MRI dojk v dobi cepljenja proti covidu-19: https://pubmed.ncbi.nlm.nih.gov/33543649/

Zmanjšanje vpliva cepljenja proti COVID-19 na pacientke, ki opravljajo slikovne preiskave dojk: pragmatičen pristop: https://pubmed.ncbi.nlm.nih.gov/33617288/

Aksilarna in cervikalna limfadenopatija, povezana s cepivom COVID-19, pri bolnikih s sedanjim ali predhodnim rakom dojke in drugimi malignimi obolenji: rezultati presečnega slikanja MRI, CT in PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892 /

Izziv postavljanja raka dojke s PET/CT v dobi cepljenja proti covidu: https://pubmed.ncbi.nlm.nih.gov/33795590/

Časovni razpored cepljenja in operacije raka dojke: https://pubmed.ncbi.nlm.nih.gov/34156582/

Enostranska aksilarna limfadenopatija, povezana s cepivom: vzorec presejalne MRI dojke: https://pubmed.ncbi.nlm.nih.gov/34325221/

Razvoj limfadenopatije pri PET/MRI po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34310229/

Aksilarna limfadenopatija po cepljenju proti COVID pri bolnikih s torakalnim malignomom: https://pubmed.ncbi.nlm.nih.gov/34506955/

DOTATATE PET-vidna aksilarna bezgavka po injiciranju Johnson & Johnson: https://pubmed.ncbi.nlm.nih.gov/34269723

DOTATATE navdušena dvostranska aksilarna in subpektoralna limfadenopatija, povzročena s cepljenjem z mRNA, prikazana na PET/CT: https://pubmed.ncbi.nlm.nih.gov/33795589/

Limfadenopatije, ki jih povzroča DOTATOC, inducirane s cepljenjem z mRNA: https://pubmed.ncbi.nlm.nih.gov/34363083/

3 primeri supraklavikularne in aksilarne limfadenopatije, povzročene s cepljenjem na 18F-Fluorthanatrace, 68Ga-DOTATATE in 18F-Fluciclovine PET/CT: https://pubmed.ncbi.nlm.nih.gov/34507331/

Vnos FDG v pazdušne bezgavke po cepljenju: primer pasti zelo sumljivih metastaz malignega melanoma v bezgavkah: https://pubmed.ncbi.nlm.nih.gov/34412144/

Cepljenje Moderna, ki posnema napredovanje bezgavk pri bolniku z melanomom: https://pubmed.ncbi.nlm.nih.gov/34433198/

COVID-19 vaccine as cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma: https://pubmed.ncbi.nlm.nih.gov/33675368/

Pfizer vaccination manifesting as incidental lymph node uptake on 18F-FDG PET/CT in a melanoma patient: https://pubmed.ncbi.nlm.nih.gov/33661193/

Axillary adenopathy following AstraZeneca resulting in possible misinterpretation of PET scan in metastatic melanoma patient: https://pubmed.ncbi.nlm.nih.gov/34414110/

8 patients where mRNA vaccine mimics lymph node metastates in patients undergoing skin cancer follow-up: https://pubmed.ncbi.nlm.nih.gov/34280870/

Hypermetabolic reactive lymphadenopathy following 3rd COVID-19 vaccination in a breast cancer patient and a patient with squamous cell carcinoma of the head and neck: https://pubmed.ncbi.nlm.nih.gov/34746900/

False Positive FDG PET CT after vaccination in a woman treated for metastatic breast cancer: https://pubmed.ncbi.nlm.nih.gov/34308402/

COVID-19 vaccine related axillary lymphadenopathy in breast cancer patients: case series with a review of the literature: https://pubmed.ncbi.nlm.nih.gov/34836672/

Pfizer vaccine related local FDG uptake in a lymphoma patient: https://pubmed.ncbi.nlm.nih.gov/33661194/

mRNA vaccination induced lymphadenopathy mimics lymphoma progression on FDG PET/CT: https://pubmed.ncbi.nlm.nih.gov/33591026/

Avid left axillary nodes and intense diffuse splenic uptake and moderate diffuse bone marrow uptake on PET 1 week after vaccination: https://pubmed.ncbi.nlm.nih.gov/34269722/

Limiting screening mammography recalls for vaccine-induced adenopathy, a single institution experience: https://pubmed.ncbi.nlm.nih.gov/35090829/

 

FDG-PET / PET-CT findings:

Vaccination effect on tracer uptake with FDG-PET/CT: https://pubmed.ncbi.nlm.nih.gov/34297113/

18-FDG-Avid lymph nodes after covid-19 vaccination on PET/CT: https://pubmed.ncbi.nlm.nih.gov/33782318/

18-FDG-Avid lymph nodes after covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33741644/

FDG update in axillary lymph nodes and deltoid muscle after mRNA vaccination: a cohort study to determine incidence and contributing factors using a multivariate analysis: https://pubmed.ncbi.nlm.nih.gov/35098436/

COVID-19 vaccination induced axillary nodal update on 18F FDG PET/CT:  https://pubmed.ncbi.nlm.nih.gov/33638003/

Prevelance and significance of hypermetabolic lymph nodes detected by 18F FDG PET/CT after vaccination: a systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34451859/

AstraZeneca vaccination included lymphadenopathy on 18F choline PET/CT-not only an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/

Abnormal PET following vaccination: https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.29262

Pozitivna PET po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34301777/

S cepivom povezana aktivacija bezgavk – vzorci privzema na PET CT: https://pubmed.ncbi.nlm.nih.gov/34131510/

Limfadenopatija pri prejemnikih cepiva: diagnostična dilema pri onkoloških bolnikih: https://pubmed.ncbi.nlm.nih.gov/33625300/

Dan po množičnem cepljenju proti COVID: večje odkrivanje hipermetabolne limfadenopatije na PET/CT in vpliv na onkološko obvladovanje: https://pubmed.ncbi.nlm.nih.gov/34503150/

Pogostost in značilnosti nodalne in deltoidne posodobitve FDG in C-holina na PET, izvedenih po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34009000/

Posodobitev FDG PET/CT v zvezi s cepljenjem proti COVID-19: nastajajoča dilema in predlogi za obvladovanje: https://pubmed.ncbi.nlm.nih.gov/33646823/

Subkutani vnos na 18F PET/CT: poročilo o morebitni imunski reaktivnosti na amiloid beta po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34541458/

Hitro napredovanje angioimunoblastnega t-celičnega limfoma po Pfizer Boosterju: https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/full?fbclid=IwAR3N-pwv8MMsjpNgb3DeEQQ5GYEGmYBQDVveSbHXvg_y5kLHDYw_2EgNsns

 

Limfom

Hitro napredovanje angioimunoblastnega T-celičnega limfoma po poživitvenem cepljenju z mRNA BNT162b2: poročilo o primeru https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/full

 

drugo:

Hiperplazija timusa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34462647/

Sindrom sistemskega kapilarnega puščanja s smrtnim izidom po cepljenju Johnson in Johnson pri bolniku z multiplim mielomom: https://pubmed.ncbi.nlm.nih.gov/34459725/

Z rituksimabom povzročena akutna limfoliza in pancitopenija po Moderni pri 71-letnem bolniku z b-celičnim limfoplazmocitnim limfomom: https://pubmed.ncbi.nlm.nih.gov/34429981/

Sindrom sistemskega kapilarnega puščanja pri ženski srednjih let po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35292552/

Neželeni učinki po cepljenju pri bolnikih z rakom, ki se zdravijo: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527840/

Rapid development of radiation recall pneumonitis in a non-small cell lung cancer patient immediately following second dose of Moderna: https://pubmed.ncbi.nlm.nih.gov/33968515/

Radiation recall pneumonitis on FDG/ PET/CT triggered by mRNA vaccination:  https://pubmed.ncbi.nlm.nih.gov/34739397/

Radiation recall pneumonitis in a non-small cell lung cancer patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34791816/

 

Dermatology/Plastics:

2 cases of denovo dermatomyositis and inflammatory myositis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35094715/

Acute, ulcerative, sarcoidal tattoo reaction in a 38yoF following 2nd dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35499440/

Eosinophilic cellulitis following Pfizer in a 12yoM: https://pubmed.ncbi.nlm.nih.gov/35522122/

Pemphigus vulgaris in a 60yoF following 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35278817/

A severe case of trichophyton rubrum-caused dermatomycosis exacerbated after Pfizer in a 75yoM: https://pubmed.ncbi.nlm.nih.gov/35299937/

Haemorrhagic bullous pyoderma gangrenosum in a 46yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35398933/

Pemphigus vulgaris in a 44yoM following 2nd dose AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35348281/

Morbilliform rash in a 30yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33560802/

6 cases of pityriasis rosea following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35698860/

Pityriasis rosea associated with covid-19 vaccination: a common rash following administration of a novel vaccine: https://pubmed.ncbi.nlm.nih.gov/35167784/

23yoF with pityriasis rosea-like rash after Pfizer: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/35156062/

40yoM with pityriasis rosea-like eruptions following Modera: a case report and literature review: https://pubmed.ncbi.nlm.nih.gov/35012825/

52yoF with pityriasis rosea-like eruption after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34557507/

53yoF with pityriasis rosea-like cutaneous eruption after AstraZenca: https://pubmed.ncbi.nlm.nih.gov/34533265/

56yoF with inverse pityriasis rosea after J&J: https://pubmed.ncbi.nlm.nih.gov/35518792/

Dermatomyositis-like rash and inflammatory myopathy after Moderna: https://pubmed.ncbi.nlm.nih.gov/35048951/

Dermatomyositis following Pfizer vaccination in a 43yoF: https://pubmed.ncbi.nlm.nih.gov/35132838/

Unilateral linear purpuric rash heralding AstraZeneca induced ITP: https://pubmed.ncbi.nlm.nih.gov/35176191/

60yo with Steven Johnson Syndrome: https://pubmed.ncbi.nlm.nih.gov/34081806/

Steven Johnson Syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34384729/

 

Pemphigus Vulgaris

Pemphigus vulgaris after COVID-19 vaccination: one new onset and two cases with severe aggravation: https://pubmed.ncbi.nlm.nih.gov/35187768/

An unusual presentation of pemphigus foliaceus following vaccination: https://pubmed.ncbi.nlm.nih.gov/34817063/

Primer eritrodermije s povišanimi serumskimi imunoglobulini E in timusom ter z aktivacijo reguliranimi ravnmi kemokinov po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34821411/

Spontana urtikarija po cepivu Pfizer: https://pubmed.ncbi.nlm.nih.gov/34692313/

Pityriasis-rosea podoben izbruh po cepljenju pri mladem moškem: https://pubmed.ncbi.nlm.nih.gov/34165237

Pityriasis rosea, izbruhi podobni pityriasis rosei in herpes zoster po cepljenju covid-19 in covid-19: https://pubmed.ncbi.nlm.nih.gov/35093476/

Pityriasis rosea po Pfizerju: https://onlinelibrary.wiley.com/doi/10.1111/jdv.17498

Pityriasis lichenoides et varioliformis acuta po okužbi s SARS-CoV2 ponovitev po cepljenju: https://pubmed.ncbi.nlm.nih.gov/35184341/

19 let s Pityriasis rosea po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34374333/

29 let s Pityriasis rosea po Moderni: https://pubmed.ncbi.nlm.nih.gov/34740803/

35 let z izbruhom, podobnim Pityriasis rosea po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/33904157/

40 let s Pityriasis rosea po Moderni: https://pubmed.ncbi.nlm.nih.gov/34110010/

66 let s Pityriasis rosea po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34435935/

1 primer Pityriasis rosea in 3 primeri urtikarije po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34478204/

2 primera izbruhov, podobnih Pityriasis rosea, po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/33982814/

Pityriasis rosea po cepljenju Moderna, serija primerov: https://pubmed.ncbi.nlm.nih.gov/34816549/

Pityriasis rosea in izbruhi, podobni pityriasis rosea, povzročeni s cepivom: pregled literature: https://pubmed.ncbi.nlm.nih.gov/25545307/

Ezematiformni izbruh po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34272069/

Dva primera papulo-pustularnih izbruhov, podobnih rozacei, po Pfizerju in AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34416044/

Pityriasis rubra pilaris po Astra Zeneca: https://pubmed.ncbi.nlm.nih.gov/34310778/

Pityriasis rubra pilaris pri 72 letih po Astra Zeneca: https://pubmed.ncbi.nlm.nih.gov/34420983/

Pityriasis Rubra Pilaris kot izbruh po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34379821/

Limfomatoidna reakcija na zdravilo, ki se je razvila po cepivu Pfizer in se kaže kot pityriasis lichenoides et varioliformis acuta podoben izbruh: https://pubmed.ncbi.nlm.nih.gov/34751995/

Lihenoidni izbruh zdravila po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35097176/

Lichenoid drug eruption after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34961975/

3 cases of new onset acral hand lesions following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34310777/

2 patients with eczematous cutaneous reactions following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236729/

Case study of 19 patients with cutaneous adverse reactions following vaccination: https://pubmed.ncbi.nlm.nih.gov/34698094/

New onset synovitis and palmoplantar psoriasis flare up after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236728/

Exacerbation of Hailey-Hailey Disease following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34436620/

New onset lichen planus following Pfizer: https://onlinelibrary.wiley.com/doi/10.1111/jdv.17504

COVID-vaccine induced lichen planus on areas previously affected by vitiligo: https://onlinelibrary.wiley.com/doi/10.1111/jdv.17687

Lichen striatus: https://pubmed.ncbi.nlm.nih.gov/34423105/

46yoM with lichen planus eruption following AstraZeneca: a case report and review of literature: https://pubmed.ncbi.nlm.nih.gov/35386174/

Linear IgA bullous dermatosis following AstraZeneca in a 61yoM: https://pubmed.ncbi.nlm.nih.gov/34762342/

60yoF with vitiligo after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35393710/

Persistent pruritic morbilliform rash after 2nd dose Pfizer in a 59yoM: https://pubmed.ncbi.nlm.nih.gov/35199304/

Lichen planus flare following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34934493/

Purpura annularis telangiectodes following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236717/

Flagellate Purpura following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416052/

Pigmented purpuric dermatosis after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34791786/

Symmetrical drug related intertriginous and flexural exanthema like eruption following AztraZeneca: https://pubmed.ncbi.nlm.nih.gov/34399001/

Vitiligo following Pfizer: https://onlinelibrary.wiley.com/doi/10.1111/ced.14842

Vitiligo in a Ulcerative Colitis Patient following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34498300/

Bacillus Calmette-Guerin scar flare after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34344774/

Palms and Soles Itchiness following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34391695/

Resistant pruritis skin rash following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34358176/

Morphea (70yoF) after AstraZeneca and a second patient after COVID-19 infection: https://pubmed.ncbi.nlm.nih.gov/35449768/

Necrotic eschars at injection sites one week after 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34337117/

Acral hemorrhage after second dose of vaccination: https://pubmed.ncbi.nlm.nih.gov/34697597/

Facial Pustular Neutrophilic Eruption following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34319363/

Acute generalized exanthematous pustulosis induced by Moderna: https://pubmed.ncbi.nlm.nih.gov/34466640/

AstraZeneca induced acute localized exanthematous pustulosis: https://pubmed.ncbi.nlm.nih.gov/34487574/

Delayed local skin reactions: https://www.nejm.org/doi/full/10.1056/NEJMc2102131?fbclid=IwAR0P6wjXiO4swT4wz0lEJCBx7v14e2Si-O9AbOuhlVisVHFhc_kGEy7pyj0

Zapoznele kožne reakcije po cepljenju z mRNA: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288253/

11 bolnikov z zapoznelo kožno reakcijo po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34433495/

Dodatnih 12 bolnikov z zapoznelimi lokalnimi reakcijami: https://www.nejm.org/doi/full/10.1056/NEJMc2102131

16 bolnikov z zapoznelo preobčutljivostno reakcijo po Moderni: https://pubmed.ncbi.nlm.nih.gov/33978670/

138 Zapoznele preobčutljivostne reakcije po cepljenju: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294276/

Zapoznele lokalne preobčutljivostne reakcije: 6-mesečna retrospektivna študija: https://pubmed.ncbi.nlm.nih.gov/34288056/

Odloženi kožni neželeni učinki zdravila AstraZeneca pri dojeni dojenčki: naključje ali redek učinek?: https://pubmed.ncbi.nlm.nih.gov/35455352/

Zapoznela kožna preobčutljivostna reakcija po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34351606/

Kožne kožne manifestacije po Moderni s preobčutljivostno reakcijo Histopatologija: https://pubmed.ncbi.nlm.nih.gov/34414254/

Ocena zapoznelih velikih lokalnih reakcij po 1. odmerku mRNA cepiva na Japonskem: https://pubmed.ncbi.nlm.nih.gov/35649530/

2 primera zapoznelih lokalnih reakcij po Moderni: https://journals.lww.com/infectdis/Fulltext/2021/07000/Delayed_Skin_Rash_After_Receiving_SARS_CoV_2_mRNA.19.aspx

4 primeri kožnih preobčutljivostnih reakcij po Moderni: https://pubmed.ncbi.nlm.nih.gov/34485656

5 japonskih primerov zapoznelih velikih lokalnih reakcij na cepljenje s Pfizerjem: https://pubmed.ncbi.nlm.nih.gov/34459023/

13 primerov zapoznelih lokalnih reakcij po cepivu mRNA: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab518/6291929

Del cepiva proti COVID: https://www.psychologytoday.com/us/blog/heal-the-mind-heal-the-body/202101/what-s-the-new-phenomenon- called-covid-vaccine-arm

COVID krak po Moderni: histološke značilnosti: https://pubmed.ncbi.nlm.nih.gov/34242422/

COVID krak po Moderni odkrit z MR nevrografijo: https://pubmed.ncbi.nlm.nih.gov/34746453/

Krak cepiva proti covidu se lahko pojavi po cepljenju z obema cepivoma mRNA: https://pubmed.ncbi.nlm.nih.gov/34416053/

405 primerov dermatoloških reakcij po Pfizerju, Moderni in Astra Zeneci: https://pubmed.ncbi.nlm.nih.gov/34254291/

Erythema migrans kot izpuščaj po Moderni: https://pubmed.ncbi.nlm.nih.gov/34250736/

Bulozna nevtrofilna dermatoza s hudim akralnim edemom po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/35092306

Bulozni pemfigoid po 2. odmerku zdravila Pfixer pri 78-letnici: https://pubmed.ncbi.nlm.nih.gov/35251600/

Bulozni pemfigoid, povezan s cepivi proti covidu-19: italijanska multicentrična študija: https://pubmed.ncbi.nlm.nih.gov/35295599/

Bulozni izpuščaj zaradi drog po Moderni: https://pubmed.ncbi.nlm.nih.gov/34294590/

Bulozni izbruh po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34416058/

Bullous Fixed Drug Eruption po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34482558/

Bulozni pemfigoid, ki ga sproži cepivo proti covidu-19 (Pfizer): hitro ozdravitev s kortikosteroidno terapijo: https://pubmed.ncbi.nlm.nih.gov/34786801/

Atipični multiformni eritem, povezan s cepivom Pfizer: https://pubmed.ncbi.nlm.nih.gov/34473839/

Multiformni eritem po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34962029/

Reakcije multiformnega eritema po Moderni in Pfizerju: serija primerov: https://pubmed.ncbi.nlm.nih.gov/35097177/

Generalizirani multiformni eritem podoben izpuščaj po Pfizerju pri 78-letnem bolniku: https://pubmed.ncbi.nlm.nih.gov/34661942/

Izbruh že obstoječega multiformnega eritema po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/33914926/

Takojšen pojav Rowellovega sindroma po prvem odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/33725406/

Anularni plaki, ki posnemajo Rowellov sindrom po cepivih mRNA: spregledan pojav? https://pubmed.ncbi.nlm.nih.gov/34693548/

4 primeri oralnega multiformnega eritema po Pfizerju (15, 55, 49 in 20 let): https://pubmed.ncbi.nlm.nih.gov/35331228/

Kožni neželeni dogodki, povezani s cepivi proti COVID-19: presečna raziskava 867 bolnikov na podlagi vprašalnika: https://pubmed.ncbi.nlm.nih.gov/34820975/

Kožne reakcije na cepivo proti covidu-19 v primarni oskrbi dermatologije (21 bolnikov): https://pubmed.ncbi.nlm.nih.gov/34837354/

Soft Tissue Filler Inflammatory Reaction after vaccination https://pubmed.ncbi.nlm.nih.gov/34174156/

Clinical and pathologic correlation of cutaneous covid-19 vaccine reactions including V-REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/

Cutaneous complications of mRNA and AstraZeneca vaccines: a worldwide review: https://pubmed.ncbi.nlm.nih.gov/35336199/

COVID related cutaneous manifestations: a systematic review: https://pubmed.ncbi.nlm.nih.gov/35141881/

A systematic review on mucocutaneous presentation after vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders: https://pubmed.ncbi.nlm.nih.gov/35316551/

New onset leukocytoclastic vasculitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33928638/

Erythema multiforme following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34676438/

Cutaneous adverse reactions associated with COV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34830627/

Cutaneous adverse events related to COVID-19 vaccines: a cross-sectional questionnaire-based study of 867 patients: https://pubmed.ncbi.nlm.nih.gov/34820975/

Soft Tissue Filler Inflammatory Reaction after vaccination: https://pubmed.ncbi.nlm.nih.gov/34174156/

;Immune Response to fillers and breast implants after vaccination: https://pubmed.ncbi.nlm.nih.gov/34174765/

Breast Implant seroma after mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34405902/

L Breast Implant Capsular Contracture following Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34373851/

COVID-prsti po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34162525/

Sistemski vaskulitis pri 80-letniku po cepljenju z mRNA, prikazan na FDG/PET: https://pubmed.ncbi.nlm.nih.gov/35175942/

2 primera vitiliga, ki ju je sprožilo cepljenje proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/35145806/

Bacillus Calmette-Guerin brazgotinski eritem pri 14 letih po cepljenju s Pfizerjem: https://pubmed.ncbi.nlm.nih.gov/35175660/

Levkocitoklastični vaskulitis: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.4191

Schnitzlerjev sindrom po cepljenju proti covidu-19: https://pubmed.ncbi.nlm.nih.gov/35650133/

Urtikarijski vaskulitis po cepljenju proti covidu-19: prikaz primera in pregled literature: https://pubmed.ncbi.nlm.nih.gov/35652448/

Eozinofilna granulomatoza s poliangiitisom pri starejši ženski po 2. odmerku zdravila Moderna: https://pubmed.ncbi.nlm.nih.gov/35165624/

Generaliziran papulovezikularni izbruh kot stranski učinek cepiva Pfizer: https://pubmed.ncbi.nlm.nih.gov/35371700/

Nov pojav levkocitoklastičnega vaskulitisa po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/33928638/

Levkocitoklastični vaskulitis po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35099065/

Izbruh levkocitoklastičnega vaskulitisa po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/33928638/

Levkocitoklastični vaskulitis pri 42yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34196469/

Levkocitoklastični vaskulitis po obnovitvenem cepljenju s cepivom Pfizer: https://pubmed.ncbi.nlm.nih.gov/34720009/

Levkocitoklastični vaskulitis pri 68yoF po AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34713472/

Indukcija kožnega levkocitoklastičnega vaskulitisa po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34853744/

Kožni vaskulitis po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34611627/

Kožni vaskulitis po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34599716/

Levkocitoklastični vaskulitis kot kožna manifestacija cepiva AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34546608/

Levkocitoklastični vaskulitis po izpostavitvi cepivu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34836739/

Urtikarijski vaskulitis po cepljenju: https://journals.lww.com/amjdermatopathology/Citation/9000/Unique_Case_of_Urticarial_Skin_Eruptions_After.97698.aspx

Urtikarijski vaskulitis: https://pubmed.ncbi.nlm.nih.gov/34369046/

Vaskulitis malih žil po Astra Zeneci: https://pubmed.ncbi.nlm.nih.gov/34310763/

Sweet-like syndrome and multiple covid-arm syndrome following covid-19 vaccine: specific patterns in a series of 192 patients: https://pubmed.ncbi.nlm.nih.gov/35653233/

Acute Posterior multifocal placoid pigment epitheliopathy after Pfizer in a 17yoM: https://pubmed.ncbi.nlm.nih.gov/35412479/

Possible case of mRNA vaccine induced small vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34705320/

Cutaneous small vessel vasculitis following J&J: https://pubmed.ncbi.nlm.nih.gov/34337124/

Cutaneous lymphocytic vasculitis following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34327795/

Pfizer induced reactivation of varicella and resulting small vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34310759/

Granulomatous vasculitis after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34237323/

Immune complex vasculitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34530771/

Relapse of microscopic polyangiitis after Pfizer vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34251683/

De novo vasculitis after Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166777/

2 cases of skin color discoloration following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34310755/

A case series of rare cutaneous adverse events following vaccination: https://pubmed.ncbi.nlm.nih.gov/34363637/

Moderna Vaccine Induced Skin Rash: https://pubmed.ncbi.nlm.nih.gov/34423142/

A Case series of Cutaneous vaccine reactions at Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/

Reactivation of BCH vaccination scars after vaccination with mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34930152/

Clinicopathological features of cutaneous reactions after mRNA vaccines, 11 cases:  https://pubmed.ncbi.nlm.nih.gov/34459036/

3 cases of vesiculobullous non-IgE-mediated cutaneous reactions to Pfizer: https://pubmed.ncbi.nlm.nih.gov/34363258/

Sweet Syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34835143/

A case of generalized sweet’s syndrome with vasculitis triggered by J&J vaccination:  https://pubmed.ncbi.nlm.nih.gov/34849386/ 

Bullous sweet syndrome following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34817862/

A narrative review of cutaneous and hypersensitivity reactions: https://pubmed.ncbi.nlm.nih.gov/34424434/

Clinical and histopathological spectrum of delayed adverse cutaneous reactions following covid-19 vaccination, a review of 12 cases: https://pubmed.ncbi.nlm.nih.gov/34292611/

SARS-CoV-2 Vaccines and the Skin: https://pubmed.ncbi.nlm.nih.gov/34483343/

COVID-19 vaccines and cutaneous adverse reactions; a review: https://pubmed.ncbi.nlm.nih.gov/33851937/

COVID-19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide: https://pubmed.ncbi.nlm.nih.gov/34556254/

Cutaneous reactions reported after Moderna and Pfizer vaccination: a registry based study of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/

Response to McManon et al’s…414 cases: https://pubmed.ncbi.nlm.nih.gov/34801633/

Kožni izvidi po cepljenju proti COVID019: pregled svetovne literature in lastnih izkušenj: https://pubmed.ncbi.nlm.nih.gov/34661927/

Pregled kožnih in alergijskih reakcij zaradi cepljenja proti covidu-19: https://pubmed.ncbi.nlm.nih.gov/34791757/

Kožne reakcije na cepiva proti covidu-19: posodobitev registra AAD/ILDS o mestu reakcije in vrsti cepiva proti covidu: https://pubmed.ncbi.nlm.nih.gov/34800601/  

Alopecija areata po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/35107173/

Alopecija areata pri 31-letniku po 2. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/35223675/

Alopecija areata pri 61 let F po 2. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/35571458/

3 primeri ponovitve alopecije arete po Pfizerju in AstraZeneci v Italiji: https://pubmed.ncbi.nlm.nih.gov/34741583/

9 primerov alopecije areate po cepljenju proti covidu: https://pubmed.ncbi.nlm.nih.gov/34931171/

Vloga okužbe s COVID in njenega cepiva pri različnih vrstah izpadanja las: https://pubmed.ncbi.nlm.nih.gov/35266262/

Nodozni eritem pri 17 letih po 2. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/35308066/

Toksična epidermalna nekroliza (TEN) pri 12yoF po 1. odmerku Pfizer: https://pubmed.ncbi.nlm.nih.gov/36000937/

Kožni neželeni učinki po Pfizerju, 20 primerov, starost 16 let in več: https://pubmed.ncbi.nlm.nih.gov/35607272/

oftalmologija:

Splošno

COVID-19, cepljenja proti COVID-19 in posledične nenormalnosti mrežnice: vzročna zveza ali naključje? https://pubmed.ncbi.nlm.nih.gov/34473193/

Po neurju: oftalmološke manifestacije cepljenja proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34826968/

Očesni neželeni učinki po cepljenju proti covidu-19: https://pubmed.ncbi.nlm.nih.gov/34559576/

Dvostranska akutna posteriorna multifokalna plakoidna pigmentna epiteliopatija (APMPPE) po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/35750434/

Očesne manifestacije po prejemu cepiva proti COVID-19: sistematični pregled: https://pubmed.ncbi.nlm.nih.gov/34960150/

Očesni neželeni učinki: pregled in posodobitev: https://pubmed.ncbi.nlm.nih.gov/33865883/

Očesni vnetni dogodki po cepljenju proti COVID-19: večnacionalna serija primerov: https://pubmed.ncbi.nlm.nih.gov/34982290/

 

Macular Neuroretinopathy:

Acute Macular Neuroretinopathy after AstraZeneca https://www.nature.com/articles/s41433-021-01610-1.epdf?fbclid=IwAR1HGawxew4SJMoHonmJsMWpWh7Fdkh29191M84BsINLsNtOYj_R6oWqrTE

Acute macular neuroretinopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34485760/

Central serous chorioretinopathy following Pfizer (38yoM military physician): https://pubmed.ncbi.nlm.nih.gov/34949501/

4 cases of serous chorioretinopathy following Pfizer (35-65yo): https://pubmed.ncbi.nlm.nih.gov/35577701/

Bilateral multifocal central serous retinopathy following Pfizer in a 32yoF: https://pubmed.ncbi.nlm.nih.gov/35599048/

Acute Central Serous Retinopathy after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34151047/

Bilateral panuveitis mimicking vogt-koyanagi-harada disease following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35113750/

Panuveitis: https://pubmed.ncbi.nlm.nih.gov/34213988/

42 cases of Uveitis and other ocular complications following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34945256/

Reduction of Visual Acuity following Pfizer: https://link.springer.com/article/10.1007/s00011-021-01476-9?fbclid=IwAR3zAvenOwPAZmuVsx9CM7bFwOliHerfJK3M3nQCMe-3BWoT4QdNCWK7cNo

Corneal Graft Rejection:

Corneal graft rejection after Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34426655/

Corneal graft rejection following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34835205/

Acute corneal graft endothelial graft rejection following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34281760/

Full thickness corneal transplant rejection 3 days following Moderna: https://pubmed.ncbi.nlm.nih.gov/34690266/

2 cases of corneal graft rejection following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33910885 

2 cases of corneal graft rejection following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34029238/

4 cases of Corneal graft rejection following Moderna: https://pubmed.ncbi.nlm.nih.gov/34620770/

Corneal graft rejection following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34827040/

Retinal vein occlusion following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35113504/

Combined central retinal artery and vein occlusion with ischemic optic neuropathy after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35079224/

Central retinal artery occlusion after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35088861/

Bilateral Retinal Detachments 10 days after mRNA vaccination 22yoF : https://www.jem-journal.com/article/S0736-4679(21)00611-9/fulltext

Retinal venous occlusion in a 28yoM after 3rd dose of AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35648014/

Exacerbation of branch retinal vein occlusion post Pfizer: https://pubmed.ncbi.nlm.nih.gov/34918688/

CMV reactivation and pericarditis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35116025/

 

Vein Occlusion / Retinal Necrosis

6 primerov retinalnih vaskularnih dogodkov po cepljenju Pfizer, Moderna, AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34835280/

Okluzija centralne mrežnične vene, ki se pojavi takoj po 2. odmerku cepiva mRNA: https://pubmed.ncbi.nlm.nih.gov/34426861/

Okluzija centralne vene po cepljenju z mRNA: prikaz primera: https://pubmed.ncbi.nlm.nih.gov/34571653/

Kombinirana okluzija centralne retinalne arterije in vene kmalu po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34791479/

Akutna nekroza mrežnice, povezana z reaktivacijo virusa varicella zoster po cepljenju s Pfizerjem pri 78-letniku: https://pubmed.ncbi.nlm.nih.gov/34802376/

Akutna nekroza mrežnice, povezana z reaktivacijo virusa varicella zoster po cepljenju s Pfizerjem pri 62-letniku: https://pubmed.ncbi.nlm.nih.gov/34851795/

Akutna nekroza mrežnice, povezana z reaktivacijo virusa varicella zoster po cepljenju s Pfizerjem pri 71-letniku: https://pubmed.ncbi.nlm.nih.gov/34541931/

 

Okulomotorna paraliza

Prehodna okulomotorna paraliza po mRNA. Cepivo: https://pubmed.ncbi.nlm.nih.gov/34369471/

 

Sprednji uveitis

Sprednji uveitis po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34289406/

21 primerov uveitisa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34369440/

 

Optična nevropatija

Primer dvostranske arteritske anteriorne ishemične optične nevropatije in primer dvostranske akutne conske okultne zunanje retinopatije po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34394876/

 

Herpes keratitis

Ponovna aktivacija herpes simpleks keratitisa po cepljenju z zdravilom AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34493563/

Ponovitev stromalnega herpesnega keratitisa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34823340/

2 primera Ipsilateral zoster opthalmicus po Moderni in Johnson and Johnson: https://pubmed.ncbi.nlm.nih.gov/34471577/

2 primera herpes zoster ofthalmicus po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34690265/

Dvostranska imunsko posredovana keratoliza po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34483273/

 

drugo:

Cepljenje in dvostranski multifokalni horoiditis: https://pubmed.ncbi.nlm.nih.gov/34406890/

34 let z dvostranskim multifokalnim horoiditisom po drugem odmerku cepljenja: https://pubmed.ncbi.nlm.nih.gov/34344280/

Akutna neboleča dvostranska zamegljenost vida po Pfizerju zaradi bolezni Vogt-Koyanagi-Hara: https://pubmed.ncbi.nlm.nih.gov/34505819/

Multimodalno slikanje akutnega foveolitisa po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34797736/

Eritem vek po cepljenju s Pfizerjem: https://pubmed.ncbi.nlm.nih.gov/34426009/

Prehodni edem vek po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34524252/

Edem diska na enem očesu in centralna serozna horioretinopatija na drugem po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34783448/

Uho, nos in grlo:

Vztrajno, enostransko tinitus po cepljenju z mRNA: https://journals.lww.com/jfmpc/Fulltext/2022/06000/Persisting,_unilateral_tinnitus_22_days_after.175.aspx

3 primeri tinitusa po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34120553/

Tinitus, povezan s cepivom COVID: pregled VAERS: https://pubmed.ncbi.nlm.nih.gov/35096388/

18 primerov idiopatske senzorinevralne izgube sluha, tinitusa in/ali vrtoglavice po Moderni/Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34267103/

18 primerov idiopatske senzorinevralne izgube sluha, tinitusa in/ali vrtoglavice po Moderni/Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34267103/

Tinitus/kohleopatija po zdravilu AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34297133/

3 primeri nenadne senzorinevralne izgube sluha po Pfizerju in AstraZeneci: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520501/

Vestibularni nevritis pri 54-letniku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34898387

Dvostranska paraliza glasilk po 3. odmerku Pfizerja, ki zahteva intubacijo in traheostomijo: https://pubmed.ncbi.nlm.nih.gov/35762144/

Razjede dvostranske sluznice neba po Moderni pri 58 let: https://pubmed.ncbi.nlm.nih.gov/35114426/

Lipschutz razjede po AstraZeneci: https://pubmed.ncbi.nlm.nih.gov/34366434/

 

ID:

Persistent varicella zoster virus infection following mRNA COVID-19 vaccination was associated with the presence of encoded spike protein in the lesion: https://onlinelibrary.wiley.com/doi/10.1002/cia2.12278

Herpes Zoster following Moderna: https://pubmed.ncbi.nlm.nih.gov/34397201/

10 cases of herpes zoster following covid vaccination: https://pubmed.ncbi.nlm.nih.gov/35746994/

2 cases (80yoF, 69yoF) of herpes ophthalmicus following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34585774/

Herpes Zoster reactivation following Moderna: https://pubmed.ncbi.nlm.nih.gov/34316506/

Herpes Zoster following mRNA vaccination in a patient with ankylosing spondylitis: https://pubmed.ncbi.nlm.nih.gov/34814659/

5 cases of Herpes Zoster following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35180059/

Zoster meningitis after Pfizer vaccination in a 39yoF: https://pubmed.ncbi.nlm.nih.gov/35186672/

1 case HSV meningitis and 2 cases herpes zoster ophthalmic following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35097240/

Ramsy Hunt syndrome following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34344559/

L-lysine in herpesvirus reactivation after AstraZeneca vaccine: a minor literature review and case report: https://pubmed.ncbi.nlm.nih.gov/34962036/

A case series of Herpes Zoster following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34363717/

2 cases of herpes zoster following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34428545/

2 cases of herpes zoster in healthy young adults following vaccination: https://pubmed.ncbi.nlm.nih.gov/34363257/

3 cases of Herpes Zoster following Vaccination (Moderna and AstraZeneca):  https://pubmed.ncbi.nlm.nih.gov/34293165/

3 cases of Herpes Zoster after covid vaccination in patients with chronic urticaria being treated with cyclosporine: https://pubmed.ncbi.nlm.nih.gov/34510694/

4 cases of Herpes Zoster (2 pfizer, 2 astrazeneca): https://pubmed.ncbi.nlm.nih.gov/34310754/

6 cases of Herpes Zoster following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33848321/

Cepiva proti COVID-19 in okužba s herpesom: https://pubmed.ncbi.nlm.nih.gov/34786482

Primer virusa varicella-zoster po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34390376/

Reaktivacija Varicella zoster in mRNA cepiva kot sprožilec: https://pubmed.ncbi.nlm.nih.gov/34316507/

40 primerov reaktivacije HSV in VZV po cepljenju z mRNA: https://pubmed.ncbi.nlm.nih.gov/34487581/

avtoimunski:

Novonastali avtoimunski pojavi po cepljenju proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34957554/  

Smernice American College of Rheumatology za cepljenje proti COVID-19: obstaja teoretično tveganje za izbruh AIIRD in potencialno tveganje za nov pojav avtoimunosti: https://onlinelibrary.wiley.com/doi/10.1002/art.41877

Sproščanje avtoprotiteles pri otrocih po cepljenju z mRNA proti korona virusu: dejavnik tveganja za multisistemski vnetni sindrom? https://www.mdpi.com/2076-393X/9/11/1353/pd

Analiza nevroloških neželenih dogodkov, o katerih so poročali v VigiBase za cepiva proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/35198288/

Možna vloga protiteles proti idiotipu pri okužbi in cepljenju s SARS-CoV-2 https://www.nejm.org/doi/10.1056/NEJMcibr211369

Ali cepiva na osnovi RNA COVID-19 ogrožajo imunsko pogojene bolezni? Kot odgovor na “potencialno antigensko navzkrižno reaktivnost med SARS-CoV-2 in človeškim tkivom z možno povezavo s povečanjem avtoimunskih bolezni” https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7833091 /

MIS-V, multisistemski vnetni sindrom:

MIS, perikarditis in HLH pri 36yoF po Astrazeneci: https://pubmed.ncbi.nlm.nih.gov/34862234/

Multisistemski vnetni sindrom pri odraslem po Pfizerju (MIS-V): https://pubmed.ncbi.nlm.nih.gov/34326117/

MIS pri 2 odraslih s kratkim intervalom med okužbo s COVID-19 in kasnejšim cepljenjem: https://pubmed.ncbi.nlm.nih.gov/35320702/

Dva primera MIS-V: 12yoM in 14yoM: https://pubmed.ncbi.nlm.nih.gov/35614536/

Dva primera MIS-V: 15 let in 17 let: https://pubmed.ncbi.nlm.nih.gov/35275051/

MIS-V pri 16-letniku 3 tedne po poživitvenem cepljenju: https://pubmed.ncbi.nlm.nih.gov/35617041/

MIS-V pri 21-letniku po 2. odmerku Pfizerja: https://pubmed.ncbi.nlm.nih.gov/35282400/

MIS, ki povzroči reverzibilno avtoimunsko kardiomiopatijo pri 25-letniku po 3. odmerku cepljenja proti COVID: https://pubmed.ncbi.nlm.nih.gov/35747051/

MIS-V z izpuščajem, podobnim multiformnemu eritemu, pri 62-letnici, ki je spremljala Pfizer: https://pubmed.ncbi.nlm.nih.gov/35248401/

Multisistemski vnetni sindrom pri odraslem po Pfizerju (MIS-V): https://pubmed.ncbi.nlm.nih.gov/34326117/

MIS-V v 22yoF po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/35719439/

Multisistemski vnetni sindrom pri 12-letnem moškem po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34978781/

Multisistemski vnetni sindrom pri 12-letnem dečku po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34955518/

MIS v 12-letni družbi Pfizer: https://pubmed.ncbi.nlm.nih.gov/35062704/

3 primeri multisistemskega vnetnega sindroma po Pfizerju: https://pubmed.ncbi.nlm.nih.gov/34034858/

Multisistemsko vnetje pri 20-letniku, ki spremlja Pfizer: https://pubmed.ncbi.nlm.nih.gov/34765984/

MIS-A v starosti 21 let po cepljenju Moderna, ki je bilo dano 27 dni po okužbi s COVID: https://pubmed.ncbi.nlm.nih.gov/34954311/

MIS-A v starosti 37 let 10 dni po 2. cepivu Moderna proti COVID in 1 mesec po okužbi s COVID: https://pubmed.ncbi.nlm.nih.gov/34868588/

Multisistemski vnetni sindrom pri otrocih s cepljenjem mladostnikov proti covidu-19 v Franciji: https://pubmed.ncbi.nlm.nih.gov/34928295/

Multisistemski vnetni sindrom pri mladostnici s srpastocelično anemijo, cepljeni s COVID-19: https://pubmed.ncbi.nlm.nih.gov/34955521/

Sproščanje avtoprotiteles pri otrocih po cepljenju z mRNA proti COVID: dejavnik tveganja za multisistemski vnetni sindrom? https://pubmed.ncbi.nlm.nih.gov/34835284/

MIS v 12-letni družbi Pfizer: https://pubmed.ncbi.nlm.nih.gov/35062704/

Multisistemski vnetni sindrom po cepljenju proti COVID-19: prezrt in premalo diagnosticiran: https://pubmed.ncbi.nlm.nih.gov/34940858/

Postmortem preiskava smrtnih primerov po cepljenju s cepivi proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/34591186/

Ugotovitve obdukcije in vzročna zveza med smrtjo in cepljenjem proti covidu-19: sistematični pregled: https://pubmed.ncbi.nlm.nih.gov/34945172/

MIS-C in a a male adolescent after his second dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34617315/

Multisystem inflammatory syndrome in an adult following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34811978/

Postvaccination MIS in an adult with no evidence of prior COVID-19 infection following AstraZeneca:https://pubmed.ncbi.nlm.nih.gov/34852213/

MIS-A in an adult woman 18 days following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34511054/

MIS in a 16yoM following 1st dose mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35187466/

MIS-A in  65yoM, Pfizer vaccine induced, with polyserositis detected by FDGMIS after J&J vaccine: https://pubmed.ncbi.nlm.nih.gov/35096528/

Fatal Multisystem inflammatory syndrome after 2nd dose of Pfizer:https://pubmed.ncbi.nlm.nih.gov/34586059/

OB/GYN:

Increased menstrual bleeding in 39,000 women after vaccination: https://www.science.org/doi/10.1126/sciadv.abm7201

2 cases of adolescents with vulvar ulcers following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35104637/

Vulvar aphthous ulcer after Pfizer in a 12yoF: https://pubmed.ncbi.nlm.nih.gov/34888935/

Vulvar aphthous ulcer in a 14yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34718079/

Vulvar aphthous ulcer in a 16yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34706274/

3 cases of acute vulvar aphthosis following Pfixer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35220345/

2 cases of adolescents with vulvar ulcers following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35104637/

Acute genital ulceration after Pfizer (12 and 14yo) and a 29yo after Moderna: https://pubmed.ncbi.nlm.nih.gov/35413297/

Miscellaneous:

Signaliziranje neželenih dogodkov cepiva proti COVID-19: https://link.springer.com/article/10.1007/s40264-022-01186-z?fbclid=IwAR0B0IFs4zK-1FK_CcjvkYw0Qvwoq35zZvxNHmJDl3dDw0Fsf3pxH5uDPwk

Konica SARS–CoV–2 poslabša popravilo poškodb DNK in zavira rekombinacijo V(D)J in vitro https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8538446/

Neželeni učinki cepiv proti covidu-19: hipoteza o skoku https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(22)00103-4

Podenota S1 konice SARS-CoV-2 inducira odzive nevrovnetne, mikroglialne in vedenjske bolezni: Dokazi o lastnostih, podobnih PAMP – BREZ virusa https://www.sciencedirect.com/science/article/pii/S0889159121006383

Cepivo BNT162b2 mRNA proti SARS-COV-2 reprogramira tako adaptivni kot prirojeni imunski odziv: https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1?fbclid=IwAR1MV3eNa-8MZFJb_SZqAF0ycaWrMM4u5_80cL2Mxyn_80cL2Mxyn_

Ali cepiva na osnovi RNK proti COVID-19 ogrožajo imunsko pogojene bolezni? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833091/

Srčno-žilni, nevrološki in pljučni dogodki po cepljenju proti COVID-19: analiza evropskih podatkov: https://pubmed.ncbi.nlm.nih.gov/34710832/

Primerjalna varnost mRNA cepiv s 433.672 ameriškimi veterani. Dodatno gradivo https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2793236

Neželeni dogodki po cepljenju proti covidu-19 v Južni Koreji od februarja do avgusta 2021: opazovalna študija po vsej državi: https://pubmed.ncbi.nlm.nih.gov/35276381/

MikroRNA zunajceličnih veziklov v obtoku, povezane z neželenimi učinki, vnetnimi citokini in proizvodnjo protiteles po cepljenju proti covidu-19: https://pubmed.ncbi.nlm.nih.gov/35136071/

Neželeni učinki cepiv proti COVID mRNA: hipoteza o skoku: https://pubmed.ncbi.nlm.nih.gov/35537987/

Neželeni učinki zdravil Pfizer in AstraZeneca v Savdski Arabiji: https://pubmed.ncbi.nlm.nih.gov/35095267/

International call for vaccine adverse reaction investigation: https://www.researchgate.net/publication/351670290_SARS-CoV-2_mass_vaccination_Urgent_questions_on_vaccine_safety_that_demand_answers_from_international_health_agencies_regulatory_authorities_governments_and_vaccine_developers?fbclid=IwAR1Gwfel6khY8ObziHNTGZriwS0Gez0CCp8zjaHllCJ9lfceD2EkJdMKmYw

Hudi stranski učinki cepiva proti COVID-19 (Pfizer) so pri starejših redki, vendar so povezani s simptomi depresije: https://pubmed.ncbi.nlm.nih.gov/34804334/

Resni neželeni dogodki po imunizaciji z AstraZeneco v Indiji, izkušnja z enim centrom: https://pubmed.ncbi.nlm.nih.gov/34804334/

Neželeni dogodki pri Pfizerju med korejskimi zdravstvenimi delavci: https://pubmed.ncbi.nlm.nih.gov/34816647/

Patofiziološke spremembe po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34697287/

Novonastala panična motnja po cepljenju Pfizer: https://pubmed.ncbi.nlm.nih.gov/35180816/

Psihoza, povezana s cepljenjem proti COVID-19: https://pubmed.ncbi.nlm.nih.gov/35180812/

Značilnosti in izidi neželenih dogodkov po cepljenju: https://pubmed.ncbi.nlm.nih.gov/34693399/

Symptomology following mRNA vaccination:https://pubmed.ncbi.nlm.nih.gov/34687733/

Neželeni učinki Pfizerja in AstraZenece po cepljenju med savdskimi cepljenimi: https://pubmed.ncbi.nlm.nih.gov/34692740/

Razširjenost resnih neželenih dogodkov po AstraZeneca v Togu: https://pubmed.ncbi.nlm.nih.gov/34819146/

Imunski mediatni dogodki, povezani z boleznijo COVOD-19, pregled podatkov za Slovenijo: https://pubmed.ncbi.nlm.nih.gov/34740853/

Zaskrbljenost zaradi neuspeha cepiva Pfizer proti divjim tipom različic po Delti in okrepljeni bolezni, povzročeni s cepivom, kot je prikazano na modelu miši: https://www.biorxiv.org/content/10.1101/2021.08.22.457114v1.full.pdf

Pomisleki glede lipidnih nanodelcev v mRNA, ki prispevajo k neželenim učinkom: https://www.biorxiv.org/content/10.1101/2021.03.04.430128v1.full?fbclid=IwAR2yUJH9kAb01O2PJ46AfBvQANuGiQvZd3ROs4R8qNJF6CZD4ds25

Poškodbe zaradi cepiva proti covidu-19 – Preprečevanje neenakosti pri nadomestilu https://www.nejm.org/doi/full/10.1056/NEJMp2034438

Komponenta lipidnih nanodelcev platforme mRNA-LNP, ki se uporablja v predkliničnih študijah cepiv, je zelo vnetljiva: https://pubmed.ncbi.nlm.nih.gov/34841223/

vir REACT 19

Oddajte komentar

Fill in your details below or click an icon to log in:

WordPress.com Logo

Komentirate prijavljeni s svojim WordPress.com računom. Odjava /  Spremeni )

Twitter picture

Komentirate prijavljeni s svojim Twitter računom. Odjava /  Spremeni )

Facebook photo

Komentirate prijavljeni s svojim Facebook računom. Odjava /  Spremeni )

Connecting to %s